Ayahuasca

'''Ayahuasca''' (also '''Yagé''', '''Hoasca''', '''Natem''') is a psychoactive brew prepared from the vine ''Banisteriopsis caapi'' (Malpighiaceae) and a [[substance:dmt]]-containing admixture plant, most commonly ''Psychotria viridis''. The vine's beta-carboline alkaloids block [[glossary:mao-a]] — the [[glossary:enzyme]] that otherwise destroys oral DMT in the gut before it can reach the brain{{cite|pubmed=6587171|anchor=fb874d76}}. With MAO-A blocked, DMT reaches the brain and activates [[glossary:serotonin]] [[glossary:receptor|receptors]], producing the [[substance_class:psychoactive/psychedelic]] state{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=2d951860}}. Ceremonial use spans centuries across dozens of indigenous groups in Brazil, Peru, Colombia, Ecuador, and Bolivia{{cite|doi=10.1017/S109285292400213X|anchor=d7b95d26}}. The pharmacological explanation — beta-carboline alkaloids enabling oral DMT activity — was established in 1984{{cite|pubmed=6587171|anchor=ccc4a252}}. Today, 26 registered clinical trials are investigating ayahuasca for [[effect:depression]], PTSD, grief, and [[glossary:addiction]]{{cite|doi=10.1002/cpt.70311|anchor=acca1079}}, with the first [[glossary:placebo-controlled-trial|randomized placebo-controlled trial]] in treatment-resistant depression showing a 64% response rate versus 27% for [[glossary:placebo]] at day 7{{cite|doi=10.1017/s0033291718001356|anchor=424b8aa3}}. [[index:effects|Subjective effects]] include vivid visual imagery, emotional [[effect:catharsis]], [[effect:ego-dissolution]], intense [[glossary:introspection]], and prominent [[effect:nausea]]{{cite|doi=10.1055/a-1675-3840|anchor=73a98f9d}}. The experience lasts 4–8 hours and is shaped as much by brew composition, setting, and psychological readiness as by dose — analyzed preparations vary 280-fold in DMT concentration{{cite|pubmed=16149328|anchor=3c4433a9}}. Purging is common and is understood in traditional contexts as part of the process, not a side effect{{cite|doi=10.1055/a-1675-3840|anchor=fdde4bec}}. Ayahuasca produces no [[glossary:physical-dependence]] and no [[glossary:withdrawal]]; observational data suggest it may reduce rather than promote addictive behavior{{cite|doi=10.1080/02791072.2016.1188225|anchor=912f874c}}. The dominant danger is the MAO-A [[glossary:inhibition]] window: combining ayahuasca with [[substance_class:psychoactive/antidepressant|antidepressants]] or other [[glossary:serotonergic-drug|serotonergic drugs]] can [[glossary:trigger]] '''serotonin syndrome''' — a potentially fatal response involving overheating, rigid muscles, and [[glossary:seizure|seizures]]{{cite|doi=10.3389/fmolb.2026.1768402|anchor=d4d672b2}}. [[glossary:animal-model|Animal studies]] show [[glossary:toxicity]] to developing fetuses, making [[glossary:pregnancy]] an absolute [[glossary:contraindication]]{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=d2d7f836}}.

'''Ayahuasca''' (also '''Yagé''', '''Hoasca''', '''Natem''') is a psychoactive decoction prepared from the vine ''Banisteriopsis caapi'' (Malpighiaceae) and a [[substance:dmt]]-containing admixture plant, typically ''Psychotria viridis''. Beta-carboline alkaloids in the vine inhibit [[glossary:mao-a]], enabling orally consumed DMT to reach the brain intact{{cite|pubmed=6587171|anchor=58566368}}. DMT then activates cortical [[glossary:5-ht2a]] [[glossary:receptor|receptors]], producing a serotonergic [[substance_class:psychoactive/psychedelic]] state{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=8fb42daf}}. Indigenous ceremonial use across northwestern Amazonia spans centuries, documented among dozens of ethnolinguistic groups in Brazil, Peru, Colombia, Ecuador, and Bolivia{{cite|doi=10.1017/S109285292400213X|anchor=5df3c607}}. The pharmacological explanation — beta-carboline MAO-A [[glossary:inhibition]] enabling oral DMT activity — was established in 1984{{cite|pubmed=6587171|anchor=3a9000ce}}, and the first [[glossary:randomized-controlled-trial]] in treatment-resistant [[effect:depression]] showed significant effects at day 7{{cite|doi=10.1017/s0033291718001356|anchor=59a4d391}}. As of 2026, 26 registered interventional trials span depression, PTSD, grief, and substance [[glossary:dependence]]{{cite|doi=10.1002/cpt.70311|anchor=9f1a2f63}}. [[index:effects|Subjective effects]] include complex visual imagery, [[effect:ego-dissolution]], cathartic emotional processing, and prominent [[effect:nausea]]{{cite|doi=10.1055/a-1675-3840|anchor=0989103b}}. The experience is deeply introspective, with set, setting, and brew composition each strongly modulating its character — inter-batch DMT concentrations range from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=f217907d}}. Purging is culturally integral in indigenous ceremonial contexts rather than an incidental side effect{{cite|doi=10.1055/a-1675-3840|anchor=aba5c505}}. No [[glossary:physical-dependence]] or [[glossary:withdrawal]] has been documented; observational data suggest anti-addictive rather than habit-forming properties{{cite|doi=10.1080/02791072.2016.1188225|anchor=b1d18d1f}}. The primary safety concern is the MAO-A inhibition window: co-administration with serotonergic [[glossary:medication|medications]] carries risk of '''serotonin syndrome'''{{cite|doi=10.3389/fmolb.2026.1768402|anchor=6c755274}}. Developmental [[glossary:toxicity]] in [[glossary:animal-model|animal models]] establishes [[glossary:pregnancy]] as a [[glossary:contraindication]]{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=06ab3d7f}}, and brew composition remains unstandardized across ceremonial and commercial preparations.

'''Ayahuasca''' (also known as '''Aya''', '''Yagé''', '''Hoasca''', '''Vegetal''', '''Natem''') is a psychoactive decoction prepared from at least two botanical components: the vine ''Banisteriopsis caapi'' (Malpighiaceae), which supplies reversible [[glossary:mao-a]] (monoamine oxidase A) inhibiting beta-carboline alkaloids, and a [[substance:dmt]]-containing admixture plant — most commonly ''Psychotria viridis'' (Rubiaceae). Consumed orally, the preparation produces a serotonergic [[substance_class:psychoactive/psychedelic]] state lasting 4–8 hours. Documented indigenous use across northwestern Amazonian cultures spans centuries and likely millennia, with ceremonial, healing, and divinatory applications recorded among dozens of ethnolinguistic groups in present-day Brazil, Peru, Colombia, Ecuador, and Bolivia{{cite|doi=10.1017/S109285292400213X|anchor=ad8366ef}}. Richard Spruce first described ''B. caapi'' during his 1849–1864 Amazonian expedition; the foundational demonstration that beta-carboline MAO-A [[glossary:inhibition]] enables oral DMT activity came in 1984{{cite|pubmed=6587171|anchor=687ca74f}}. The first [[glossary:randomized-controlled-trial]] in treatment-resistant [[effect:depression]] reported a Cohen's d of 1.49 at day 7{{cite|doi=10.1017/s0033291718001356|anchor=bb9a035f}}, and 26 registered interventional trials now span Phase I through Phase II [[glossary:indication|indications]] including depression, PTSD, grief, and substance [[glossary:dependence]]{{cite|doi=10.1002/cpt.70311|anchor=f0c92d56}}. The beta-carbolines [[substance:harmine]], [[substance:harmaline]], and tetrahydroharmine in ''B. caapi'' reversibly inhibit intestinal and hepatic MAO-A, preventing [[glossary:first-pass-metabolism|first-pass]] oxidative deamination of orally consumed DMT{{cite|pubmed=6587171|anchor=1d897757}}. DMT then crosses the blood–brain barrier and acts as a [[glossary:partial-agonist]] at cortical [[glossary:5-ht2a]] [[glossary:receptor|receptors]] — the principal mediator of its psychedelic effects, confirmed by ketanserin [[glossary:blockade]] in humans{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=7d03583d}}. Tetrahydroharmine additionally acts as a weak [[substance_class:pharmacological/serotonin-reuptake-inhibitor]], potentially contributing an [[substance_class:psychoactive/anxiolytic]] component{{cite|doi=10.1590/1516-4446-2020-0884|anchor=5100de72}}. The resulting experience encompasses complex visual imagery, [[effect:ego-dissolution]], cathartic emotional processing, and prominent [[effect:nausea]] and purging — the latter culturally integral in indigenous ceremonial contexts{{cite|doi=10.1055/a-1675-3840|anchor=d26306d1}}. Effects and duration vary substantially by brew composition, with inter-batch DMT concentrations ranging from 0.05 to 14.2 mg/mL across analyzed preparations{{cite|pubmed=16149328|anchor=3d03701d}}. The primary safety concern is the MAO-A inhibition window: co-administration with serotonergic [[glossary:medication|medications]] (SSRIs, SNRIs, MAOIs, [[substance:tramadol]]) carries risk of '''serotonin syndrome''', a life-threatening emergency{{cite|doi=10.3389/fmolb.2026.1768402|anchor=f9618b1b}}. No [[glossary:physical-dependence]] or characteristic [[glossary:withdrawal]] has been documented; observational data suggest anti-addictive rather than habit-forming properties{{cite|doi=10.1080/02791072.2016.1188225|anchor=12d07c88}}. Developmental [[glossary:toxicity]] has been demonstrated in [[glossary:animal-model|animal models]] at supratherapeutic doses{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=113741dc}}, establishing [[glossary:pregnancy]] as a [[glossary:contraindication]]. Brew composition is unstandardized — alkaloid content, [[glossary:contamination|contaminant]] risk, and undisclosed admixture plants vary across ceremonial and commercial preparations, and no ISO-accredited quality-control framework exists for traditional ayahuasca.

===Traditional and indigenous use=== Ayahuasca use has been documented across dozens of indigenous ethnolinguistic groups throughout northwestern Amazonia — spanning present-day Brazil, Peru, Colombia, Ecuador, Bolivia, and Venezuela — with ceremonial contexts including healing, divination, initiation, and spiritual purification{{cite|doi=10.1017/S109285292400213X|anchor=d990015b}}{{cite|doi=10.1055/a-1675-3840|anchor=fff12d41}}. Regional naming conventions reflect this breadth: ''ayahuasca'' (Quechua), ''natem'' (Shuar, Ecuador), ''yagé'' (Tukano, Colombia), ''hoasca'' and ''vegetal'' (Brazilian syncretic churches). The emetic and purgative effects are culturally integral — understood as physical and spiritual cleansing (''la purga'') rather than an adverse reaction{{cite|doi=10.1055/a-1675-3840|anchor=cf703a1f}}. The chronological depth of this tradition is not precisely dated; ethnographic documentation spans at least the 17th century{{cite|doi=10.3389/fphar.2016.00035|anchor=52f96cf6}}. {{Info}}Traditional-use accounts in this section derive from ethnographic and ethnobotanical literature. Published primary documentation of indigenous ayahuasca use prior to 1980 is predominantly anthropological in format and has not been replicated under controlled pharmacological conditions.{{/Info}} ===Western discovery and research=== Richard Spruce, an English botanist, first formally described the ayahuasca vine during his 1849–1864 Amazonian expedition, publishing it as ''Banisteria caapi''; the accepted binomial ''Banisteriopsis caapi'' was formalized in 1931{{cite|url=https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:29180-2|anchor=6c3ee8f8}}. [[substance:harmine]], [[substance:harmaline]], and [[substance:dmt]] were isolated and chemically identified from ''B. caapi'' and admixture plants during 1958–1960. In 1984, McKenna, Towers, and Abbott demonstrated that beta-carboline alkaloids function as [[glossary:mao-a]] [[glossary:inhibitor|inhibitors]], providing the pharmacological explanation for oral DMT activity{{cite|pubmed=6587171|anchor=9fd25e05}}. Riba, Barbanoj, and colleagues in Barcelona initiated the first European [[glossary:double-blind]] controlled [[glossary:clinical-study|clinical studies]] between 1999 and 2003{{cite|pubmed=12660312|anchor=9b2e211d}}{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=f62b2cbb}}. The first fMRI neuroimaging study demonstrated [[glossary:default-mode-network]] suppression in 2015{{cite|doi=10.1371/journal.pone.0118143|anchor=49d3d78a}}. ===Modern research and regulation=== Brazil's National Council on Drug Policy (CONAD) first formally regulated ayahuasca in 1987, authorizing religious and ceremonial use — establishing the world's first national regulatory framework for the preparation. The U.S. Supreme Court ruled in 2006 (''Gonzales v. O Centro'') that the Religious Freedom Restoration Act protected UDV sacramental use. Peru declared ceremonial use a national cultural heritage in 2008. Colorado decriminalized natural [[substance_class:psychoactive/psychedelic|psychedelics]] including ayahuasca via Proposition 122 in November 2022{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=d7ff173b}}. The first [[glossary:placebo-controlled-trial|randomized placebo-controlled trial]] in treatment-resistant [[effect:depression]], published in 2018, reported a response rate of 64% versus 27% for [[glossary:placebo]] at day 7{{cite|doi=10.1017/s0033291718001356|anchor=d63edab9}}. As of 2026, 26 registered interventional trials span depression, PTSD, grief, and substance [[glossary:dependence]]{{cite|doi=10.1002/cpt.70311|anchor=01315562}}. Meta-analytic data report a Hedges' g of −1.34 (95% CI −1.86 to −0.82) for ayahuasca and DMT in mood [[glossary:disorder|disorders]]{{cite|doi=10.1016/j.psychres.2024.115886|anchor=ff30eabc}}, though broader pooled analysis yields a more conservative [[glossary:effect-size]] at very low evidence certainty{{cite|doi=10.1016/j.euroneuro.2025.09.011|anchor=a44aa6f5}}. {{DiscoverMore|Culture and lore}} The name ''ayahuasca'' derives from Quechua: ''aya'' (spirit, ancestor, or dead person) and ''huasca'' (vine or rope) — commonly translated as "vine of the soul" or "vine of the dead." The brew occupies a central role in Amazonian cosmology, understood as a teacher and diagnostic tool rather than a recreational substance. In Brazilian syncretic churches — Santo Daime (founded 1930s) and União do Vegetal (founded 1961) — ayahuasca is consumed as a sacrament within structured liturgical services. {{/DiscoverMore}}

===Traditional and indigenous use=== Ayahuasca has been used ceremonially for centuries across dozens of indigenous groups in northwestern Amazonia — in present-day Brazil, Peru, Colombia, Ecuador, Bolivia, and Venezuela{{cite|doi=10.1017/S109285292400213X|anchor=1b7bd5a7}}{{cite|doi=10.1055/a-1675-3840|anchor=8642d02f}}. Ceremonial uses include healing, divination, initiation, and spiritual purification. The brew carries different names across cultures: ''ayahuasca'' (Quechua), ''natem'' (Shuar, Ecuador), ''yagé'' (Tukano, Colombia), and ''hoasca'' or ''vegetal'' in Brazilian syncretic churches. Ethnographic documentation extends at least to the 17th century{{cite|doi=10.3389/fphar.2016.00035|anchor=43a261d9}}. Emetic and purgative effects are culturally integral — understood as cleansing rather than a side effect{{cite|doi=10.1055/a-1675-3840|anchor=5bce9d44}}. {{Info}}Traditional-use accounts in this section derive from ethnographic and ethnobotanical literature. Published primary documentation of indigenous ayahuasca use prior to 1980 is predominantly anthropological in format and has not been replicated under controlled pharmacological conditions.{{/Info}} ===Western discovery and research=== The English botanist Richard Spruce formally described the vine during his 1849–1864 Amazonian expedition; the accepted binomial ''Banisteriopsis caapi'' was formalized in 1931{{cite|url=https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:29180-2|anchor=e29fe4cd}}. In 1984, McKenna, Towers, and Abbott established that the beta-carboline alkaloids act as [[glossary:mao-a]] [[glossary:inhibitor|inhibitors]] — explaining why [[substance:dmt]] is active when consumed orally{{cite|pubmed=6587171|anchor=2203c891}}. The first European [[glossary:double-blind]] controlled [[glossary:clinical-study|clinical studies]] ran from 1999 to 2003{{cite|pubmed=12660312|anchor=dfb09e60}}{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=744261a3}}, and a first fMRI study confirmed [[glossary:default-mode-network]] suppression in 2015{{cite|doi=10.1371/journal.pone.0118143|anchor=dc939444}}. ===Modern research and regulation=== Brazil first formally regulated ayahuasca in 1987, authorizing religious and ceremonial use — the world's first national regulatory framework for the preparation. The U.S. Supreme Court upheld Religious Freedom Restoration Act protections for the União do Vegetal in 2006; Peru declared ceremonial use a national cultural heritage in 2008. The first [[glossary:placebo-controlled-trial|randomized placebo-controlled trial]] in treatment-resistant [[effect:depression]], published in 2018, reported a 64% response rate versus 27% for [[glossary:placebo]]{{cite|doi=10.1017/s0033291718001356|anchor=712df14d}}, and 26 registered interventional trials are active as of 2026{{cite|doi=10.1002/cpt.70311|anchor=ec5fbcf7}}. Meta-analytic data report a large pooled [[glossary:effect-size]] in mood [[glossary:disorder|disorders]]{{cite|doi=10.1016/j.psychres.2024.115886|anchor=a8867ed4}}, though broader pooled analysis yields a more conservative estimate at very low evidence certainty{{cite|doi=10.1016/j.euroneuro.2025.09.011|anchor=21495d61}}. {{DiscoverMore|Culture and lore}} The name ''ayahuasca'' derives from Quechua: ''aya'' (spirit, ancestor, or dead person) and ''huasca'' (vine or rope) — commonly translated as "vine of the soul" or "vine of the dead." The brew occupies a central role in Amazonian cosmology, understood as a teacher and diagnostic tool rather than a recreational substance. In Brazilian syncretic churches — Santo Daime (founded 1930s) and União do Vegetal (founded 1961) — ayahuasca is consumed as a sacrament within structured liturgical services. {{/DiscoverMore}}

===Discovery and early record=== Richard Spruce, an English botanist, first formally described the ayahuasca vine during his 1849–1864 expedition through the Amazon basin, publishing it as ''Banisteria caapi'' Spruce ex Griseb. in 1858. The accepted binomial ''Banisteriopsis caapi'' (Spruce ex Griseb.) C.V.Morton was formalized in 1931{{cite|url=https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:29180-2|anchor=b77397a6}}. Spruce documented ceremonial vine use among the Tukano people of the Rio Negro region in Brazil, producing one of the earliest Western accounts of ayahuasca preparation and consumption. ===Traditional and indigenous use=== Ayahuasca use has been documented across dozens of indigenous ethnolinguistic groups throughout northwestern Amazonia — spanning present-day Brazil, Peru, Colombia, Ecuador, Bolivia, and Venezuela — with ceremonial contexts including healing, divination, initiation rites, and spiritual purification{{cite|doi=10.1017/S109285292400213X|anchor=1019d3e7}}{{cite|doi=10.1055/a-1675-3840|anchor=3e6ec95c}}. Regional naming conventions reflect this breadth: ''ayahuasca'' and ''natem'' (Shuar, Ecuador), ''yagé'' and ''yajé'' (Tukano/Desana, Colombia), ''hoasca'' and ''vegetal'' (Brazilian syncretic churches), ''caapi'' (various Brazilian groups), and ''cipó'' (Portuguese, used in Santo Daime traditions). The emetic and purgative effects of the brew are culturally integral — framed as ''la purga'' (the purge) and understood as physical and spiritual cleansing rather than an adverse effect{{cite|doi=10.1055/a-1675-3840|anchor=204aadf2}}. The chronological depth of this tradition is not precisely dated; archaeological evidence is limited, but ethnographic documentation spans at least the 17th century{{cite|doi=10.3389/fphar.2016.00035|anchor=d56251fc}}{{flag|claim-unsupported}}. {{Info}}Traditional-use accounts in this section derive from ethnographic and ethnobotanical literature. Published primary documentation of indigenous ayahuasca use prior to 1980 is predominantly anthropological in format and has not been replicated under controlled pharmacological conditions.{{/Info}} ===Western encounter and research=== Richard Evans Schultes conducted extensive ethnobotanical fieldwork across Colombia and Peru from the 1940s through the 1960s, producing foundational monographs on ayahuasca botany and use{{flag|citation-needed}}. [[substance:harmine]], [[substance:harmaline]], and [[substance:dmt]] were isolated and chemically identified from ''B. caapi'' and admixture plants during the 1958–1960s. In 1984, McKenna, Towers, and Abbott demonstrated that the beta-carboline alkaloids function as [[glossary:mao-a]] [[glossary:inhibitor|inhibitors]], providing the pharmacological explanation for oral DMT activity — an additive rather than synergistic mechanism{{cite|pubmed=6587171|anchor=a9596916}}. The Hoasca Project (Callaway, Grob, and colleagues, 1993–2000) conducted the first systematic human pharmacological and psychological studies of ayahuasca in members of the União do Vegetal (UDV) church in Brazil{{flag|citation-needed}}. Riba, Barbanoj, and colleagues in Barcelona initiated the first European [[glossary:double-blind]] controlled [[glossary:clinical-study|clinical studies]] between 1999 and 2003{{cite|pubmed=12660312|anchor=acc53169}}{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=b9260cfd}}. ===Regulatory milestones=== Brazil's National Council on Drug Policy (CONAD) first formally regulated ayahuasca in 1987, authorizing religious and ceremonial use — establishing the world's first national regulatory framework for the preparation. In 2006, the United States Supreme Court ruled in ''Gonzales v. O Centro Espírita Beneficente União do Vegetal'' that the Religious Freedom Restoration Act (RFRA) protected UDV sacramental use; Santo Daime received comparable protection subsequently. Peru declared ceremonial ayahuasca use a national cultural heritage in 2008. The Netherlands Supreme Court reversed prior lower-court decisions in 2019, ruling ayahuasca prohibited under the Opium Act due to its DMT content. Colorado decriminalized natural [[substance_class:psychoactive/psychedelic|psychedelics]] including ayahuasca via Proposition 122 in November 2022{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=69053fa4}}. ===Modern research era=== The first fMRI neuroimaging study of ayahuasca demonstrated [[glossary:default-mode-network]] suppression in 2015{{cite|doi=10.1371/journal.pone.0118143|anchor=f6ddb904}}. The first [[glossary:placebo-controlled-trial|randomized placebo-controlled trial]] in treatment-resistant [[effect:depression]], published in 2018, reported a response rate of 64% versus 27% for [[glossary:placebo]] at day 7{{cite|doi=10.1017/s0033291718001356|anchor=5e84152c}}. As of 2026, 26 registered interventional trials span depression, PTSD, premenstrual symptoms, grief, and mechanistic imaging studies, with the majority in Phase I and primarily sponsored by academic institutions{{cite|doi=10.1002/cpt.70311|anchor=b79e89e0}}. Meta-analytic data report a Hedges' g of −1.34 (95% CI −1.86 to −0.82) for ayahuasca and DMT in mood [[glossary:disorder|disorders]]{{cite|doi=10.1016/j.psychres.2024.115886|anchor=f9020d54}}, though a broader pooled analysis of [[glossary:serotonergic-psychedelics]] for major depressive disorder yields a more conservative SMD of −0.62 (95% CI −0.97 to −0.28) at very low GRADE evidence certainty{{cite|doi=10.1016/j.euroneuro.2025.09.011|anchor=961e7380}}.

Ayahuasca is a botanical preparation, not a single plant species. The decoction requires at minimum two components: a beta-carboline-containing vine providing [[glossary:mao-a]] [[glossary:inhibition]], and a [[substance:dmt]]-containing admixture plant providing the primary [[substance_class:psychoactive/psychedelic]] constituent. This section describes the botanical identity of each component. ===''Banisteriopsis caapi'' (vine)=== ''Banisteriopsis caapi'' (Spruce ex Griseb.) C.V.Morton is a large woody liana of the family Malpighiaceae, reaching up to 30 m in length in its native wet tropical biome. The stem bark is chocolate-brown and smooth; leaves are opposite, oval, 8–18 cm long and 3.5–8 cm wide; flowers are white to pale pink, 12–14 mm in diameter. The genus ''Banisteriopsis'' contains approximately 90 species, of which ''B. caapi'' is the most pharmacologically significant due to its beta-carboline alkaloid content{{cite|url=https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:29180-2|anchor=8d1a203c}}. Accepted synonyms include ''Banisteria caapi'' Spruce ex Griseb. (homotypic), ''Banisteria inebrians'' (C.V.Morton) J.F.Macbr., ''Banisteria quitensis'' Nied., ''Banisteriopsis inebrians'' C.V.Morton, and ''Banisteriopsis quitensis'' (Nied.) C.V.Morton{{cite|url=https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:29180-2|anchor=6f816a24}}. The vine is actively cultivated by indigenous communities for ceremonial use and wild-collected throughout its native range in Argentina (Northwest), Bolivia, Brazil (North and West-Central), Colombia, Ecuador, Peru, and Venezuela. ===''Psychotria viridis'' (admixture leaf)=== ''Psychotria viridis'' Ruiz & Pav. is a perennial shrub of the family Rubiaceae, native to tropical Amazonian rainforests. Known as ''chacruna'' in Peru and Brazil, it serves as the primary DMT-containing admixture in most ayahuasca preparations. Leaf DMT content ranges from 0.1 to 0.61% dry weight; analytical study of 37 Brazilian samples found a range of 0.00–17.65 mg/g dried leaf, with an average of approximately 10 mg/g{{cite|url=https://erowid.org/plants/psychotria/psychotria_info1.shtml|anchor=df2ae2b8}}. Daily variation in DMT concentration has been documented, with highest levels at dawn and pre-dusk collections. ===Alternative admixture plants=== Two additional admixture species have been documented in traditional preparations. ''Diplopterys cabrerana'' (Malpighiaceae), known as chagropanga or chaliponga, contains DMT and is used in western Amazonian regions of Colombia and Ecuador. ''Psychotria carthagenensis'' Jacq. (amyruca) is used less commonly{{cite|pubmed=6587171|anchor=00d16319}}. No published human pharmacokinetic studies compare the effects of these admixture substitutions on brew [[glossary:potency]] or DMT [[glossary:bioavailability]]. ===Misidentification and adulteration risk=== Multiple ''Banisteriopsis'' species exist, some without significant alkaloid content. Among experienced traditional practitioners, the vine's morphological distinctiveness and established cultivar recognition reduce identification error at the source. Commercial preparations from unverified suppliers carry higher [[glossary:misidentification]] and [[glossary:adulterant|adulteration]] risk — ceremonial brews may include undisclosed admixture plants such as ''Brugmansia'' or ''Datura'' species containing [[substance_class:chemical/tropane]] alkaloids ([[substance:scopolamine]], atropine), which produce an anticholinergic [[glossary:toxicity|toxicity profile]] mechanistically distinct from ayahuasca's serotonergic effects.

''Banisteriopsis caapi'' (Spruce ex Griseb.) C.V.Morton belongs to the family Malpighiaceae. It is a large woody climbing vine native to the tropical lowland forests of the Amazon basin and adjacent South American regions. ''Psychotria viridis'' Ruiz & Pav. (Rubiaceae), the most common [[substance:dmt]]-containing admixture plant, is an understory shrub native to the same Amazonian forests. Both species are cultivated in tropical gardens throughout South America and increasingly worldwide. Wild populations remain abundant in intact Amazonian forest. The vine is harvested by cutting mature stems into sections; ''P. viridis'' leaves are picked fresh for brewing. ''B. caapi'' is identified by its smooth greyish-brown bark that peels in longitudinal strips, opposite leaves, and a distinctive pattern of concentric rings in cross-section. ''P. viridis'' has glossy dark green elliptical leaves with prominent venation and small red berrylike fruits. ''Diplopterys cabrerana'' — known as ''chagropanga'' or ''chaliponga'' — serves as the DMT source in some Colombian and Ecuadorian traditions in place of ''P. viridis''. Additional botanicals including tobacco (''Nicotiana rustica'') and ''Brugmansia'' species may be added to specific ceremonial preparations, significantly altering the pharmacological and safety profile.

''Banisteriopsis caapi'' (Spruce ex Griseb.) C.V.Morton belongs to the family Malpighiaceae. It is a large woody liana — a climbing vine — native to the tropical lowland forests of the Amazon basin and adjacent regions of South America. The vine can reach substantial lengths, wrapping around host trees to access the forest canopy. ''Psychotria viridis'' Ruiz & Pav. (Rubiaceae), the most common [[substance:dmt]]-containing admixture, is an understory shrub native to the same lowland Amazonian forests. ''B. caapi'' is identified by its smooth, greyish-brown bark that peels in longitudinal strips, opposite leaves, and small pink or pale flowers borne in axillary clusters. The vine's cross-section reveals a distinctive pattern of concentric rings. ''P. viridis'' is recognized by its glossy, dark green, elliptical leaves with prominent venation and small red berrylike fruits. Both species are cultivated in tropical gardens throughout South America and increasingly in tropical regions worldwide. Wild populations remain abundant in intact Amazonian forest. The vine is typically harvested by cutting mature stems into sections, while ''P. viridis'' leaves are picked fresh for brewing. Alternative DMT-containing admixture plants are used regionally, most notably ''Diplopterys cabrerana'' (Malpighiaceae) — known as ''chagropanga'' or ''chaliponga'' — which replaces ''P. viridis'' in some Colombian and Ecuadorian traditions. Additional admixture botanicals — including tobacco (''Nicotiana rustica''), ''Brugmansia'' species, and others — may be added to specific ceremonial preparations, significantly altering the pharmacological and safety profile.

Ayahuasca's effects arise from two alkaloid classes working together. The vine ''B. caapi'' supplies beta-carboline alkaloids — primarily [[substance:harmine]], [[substance:harmaline]], and tetrahydroharmine — that block [[glossary:mao-a]], the [[glossary:enzyme]] that would otherwise break down [[substance:dmt]] in the gut before it reaches the brain. Without that block, orally consumed DMT is roughly 97% metabolized before reaching the brain and produces no psychoactive effect{{cite|doi=10.1002/dta.1685|anchor=f817f8bc}}. Harmine is the most abundant beta-carboline and the primary MAO-A [[glossary:inhibitor]]{{cite|pubmed=6587171|anchor=7d839e4e}}; it also inhibits the [[glossary:dopamine-transporter]]{{cite|doi=10.1016/j.pnpbp.2012.06.001|anchor=8b10baf5}}. Harmaline acts as a secondary MAO-A inhibitor with greater preclinical [[glossary:toxicity]] concerns than harmine{{cite|doi=10.1177/10915818241230916|anchor=b6a64994}}. Tetrahydroharmine inhibits [[glossary:reuptake|serotonin reuptake]] — a separate mechanism that may contribute a mild [[substance_class:psychoactive/anxiolytic]] component{{cite|doi=10.1590/1516-4446-2020-0884|anchor=933d0c1a}}{{cite|doi=10.3390/biom12111618|anchor=3c34a03d}}. The admixture plant provides DMT, which activates [[glossary:serotonin]] [[glossary:receptor|receptors]] in the [[glossary:cortex]] and drives the [[substance_class:psychoactive/psychedelic]] state{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=33458d44}}; DMT also engages several other [[glossary:receptor-system|receptor systems]]{{cite|doi=10.1017/S109285292400213X|anchor=0e63ded2}}{{cite|doi=10.1007/s00018-024-05353-6|anchor=69b58e83}}{{cite|doi=10.3390/biom12111618|anchor=a505204f}}{{cite|doi=10.3389/fphar.2016.00035|anchor=01374ce7}}. Alkaloid concentrations vary dramatically between preparations. Analyzed brews show DMT concentrations ranging from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=81751697}} — a 280-fold spread. Vine-to-leaf ratios, brewing duration, water volume, and plant cultivar all contribute. A "standard dose" cannot be established without laboratory testing.

===Beta-carbolines in ''Banisteriopsis caapi''=== The vine supplies three pharmacologically active beta-carboline alkaloids. Quantitative analyses of dried stem material report the following concentration ranges:

Alkaloid	Dry stem content	Mean (mg/g)	Primary action
Harmine (C₁₃H₁₂N₂O, MW 212.25)	0.31–8.43%	~4.79	Reversible, competitive MAO-A inhibitor; DYRK1A inhibitor; dopamine transporter inhibitor{{cite|doi=10.1016/j.pnpbp.2012.06.001|anchor=75ba1860}}
Harmaline (C₁₃H₁₄N₂O, MW 214.26)	0.03–0.83%	~0.451	Reversible MAO-A inhibitor; most toxic beta-carboline in preclinical models{{cite|doi=10.1177/10915818241230916|anchor=c81d817d}}
Tetrahydroharmine (THH; C₁₃H₁₆N₂O, MW 216.28)	0.05–2.94%	~2.18	Weak serotonin reuptake inhibitor (SERT); minor MAO-A inhibition{{cite|doi=10.1590/1516-4446-2020-0884|anchor=88283449}}

Data derived from analytical studies of dried vine material{{cite|pubmed=6587171|anchor=a7f8811f}}{{cite|pubmed=16149328|anchor=7c192d69}}{{flag|claim-unsupported}}{{cite|doi=10.1016/j.jep.2010.02.013|anchor=d6007022}}{{cite|url=https://www.researchgate.net/figure/Alkaloid-contents-of-Banisteriopsis-caapi-dry-stems|anchor=f340e4b1}}. [[substance:harmine]] is the dominant alkaloid by concentration; it constitutes the primary pharmacological driver of the [[glossary:mao-a]] [[glossary:inhibition]] that enables oral [[substance:dmt]] activity. Considerable inter-sample variability — up to 27-fold in harmine content — has been documented across cultivars, geographic sources, and harvest batches{{cite|pubmed=16149328|anchor=d2bc1333}}{{flag|claim-unsupported}}. Tetrahydroharmine is the second most abundant alkaloid and may form additionally from harmine and [[substance:harmaline]] during the boiling process of traditional preparation{{cite|pubmed=16149328|anchor=b51fd2e8}}{{flag|claim-unsupported}}. Minor beta-carbolines including harmine-N-oxide and harmane are present in trace quantities. Published evidence for pharmacologically significant contributions of these minor constituents at concentrations found in typical brews is limited. ===DMT in admixture plants=== DMT (N,N-dimethyltryptamine; C₁₂H₁₆N₂, MW 188.27) is the primary [[substance_class:psychoactive/psychedelic]] constituent, derived from ''P. viridis'' leaves at 0.1–0.61% dry weight; analytical study of 37 Brazilian samples found concentrations of 0.00–17.65 mg/g dried leaf with a mean of approximately 10 mg/g{{cite|url=https://erowid.org/plants/psychotria/psychotria_info1.shtml|anchor=32ba861d}}. Trace N-methyltryptamine (MMT) is also present{{cite|pubmed=6587171|anchor=de4f4e1f}}. ===Brew composition=== Analysis of prepared ayahuasca brews reveals wide variability in alkaloid content. DMT concentrations range from 0.05 to 14.2 mg/mL across analyzed samples; Brazilian religious brews typically contain 0.24–0.36 mg/mL (24–36 mg per 100 mL serving){{cite|pubmed=16149328|anchor=520d0cb5}}{{flag|claim-unsupported}}{{cite|doi=10.1016/j.jchromb.2019.06.014|anchor=2d570209}}{{flag|claim-unsupported}}. Forensic analysis of seized preparations reports 45.7–230.5 mg/L{{cite|doi=10.1016/j.jchromb.2019.06.014|anchor=fa493a09}}{{flag|claim-unsupported}}. A typical ceremonial serving of approximately 100 mL delivers 25–100 mg DMT. No standardized composition exists; the alkaloid profile is entirely preparation-dependent. ===Preparation effects on constituent ratios=== Traditional preparation involves prolonged aqueous decoction — boiling ''B. caapi'' stem and bark together with ''P. viridis'' leaves for several hours, straining, repeating the extraction, and reducing the combined liquid. During extended boiling, tetrahydroharmine may form from harmine and harmaline via thermal reduction{{cite|pubmed=16149328|anchor=616a7347}}{{flag|claim-unsupported}}. Unlike [[substance:cannabis]], where heat drives decarboxylation of THCA to THC, the ayahuasca boiling process does not alter core alkaloid structures but concentrates all alkaloids proportionally through volume reduction. Alkaloid content in prepared brews remains stable at room temperature for approximately 80 days{{cite|pubmed=16149328|anchor=6a02dadc}}{{flag|claim-unsupported}}.

Ayahuasca's psychoactive properties arise from the interaction of two distinct alkaloid classes sourced from separate plants. The vine ''B. caapi'' contributes beta-carboline alkaloids — primarily [[substance:harmine]], [[substance:harmaline]], and tetrahydroharmine — which function as reversible [[glossary:mao-a]] [[glossary:inhibitor|inhibitors]]. The admixture plant (typically ''P. viridis'') supplies [[substance:dmt]] (''N'',''N''-dimethyltryptamine), a [[substance_class:chemical/tryptamine]] [[substance_class:psychoactive/psychedelic]]. Without MAO-A [[glossary:inhibition]], orally consumed DMT is approximately 97% metabolized to inactive [[substance_class:chemical/indole]]-3-acetic acid during [[glossary:first-pass-metabolism]] and produces no psychotropic effects{{cite|doi=10.1002/dta.1685|anchor=2b3010d8}}. Harmine is typically the most abundant beta-carboline in ''B. caapi'' and serves as the primary MAO-A inhibitor enabling oral DMT activity{{cite|pubmed=6587171|anchor=46f4de19}}. Harmine also inhibits DYRK1A kinase and the [[glossary:dopamine-transporter]]{{cite|doi=10.1016/j.pnpbp.2012.06.001|anchor=aa169c87}}. Harmaline acts as a secondary MAO-A inhibitor with greater preclinical [[glossary:toxicity]] concerns than harmine{{cite|doi=10.1177/10915818241230916|anchor=78e63fc4}}. Tetrahydroharmine functions as a weak [[substance_class:pharmacological/serotonin-reuptake-inhibitor]], potentially contributing an [[substance_class:psychoactive/anxiolytic]] component independent of DMT's psychedelic effects{{cite|doi=10.1590/1516-4446-2020-0884|anchor=eff087f3}}{{cite|doi=10.3390/biom12111618|anchor=bb01c317}}. DMT acts as a [[glossary:partial-agonist]] at [[glossary:5-ht2a]] [[glossary:receptor|receptors]] — the receptor primarily responsible for its psychedelic effects{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=b9725c03}}. It also engages [[glossary:5-ht1a]], [[glossary:5-ht2c]], [[glossary:taar1]] (TAAR1), and [[glossary:sigma-1-receptor|sigma-1 receptors]]{{cite|doi=10.1017/S109285292400213X|anchor=fbadd3cc}}{{cite|doi=10.1007/s00018-024-05353-6|anchor=3121c24e}}{{cite|doi=10.3390/biom12111618|anchor=c5d0cf4d}}{{cite|doi=10.3389/fphar.2016.00035|anchor=261a0543}}. Alkaloid concentrations vary dramatically across preparations. Analyzed ayahuasca brews show inter-batch DMT concentrations ranging from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=f6bc917b}}, making dose estimation unreliable without analytical verification. Vine-to-leaf ratios, brewing duration, water volume, and plant cultivar all contribute to this variability.

===Where it acts=== Following [[glossary:mao-a]] [[glossary:inhibition]] by the beta-carbolines, [[substance:dmt]] crosses the blood–brain barrier and activates [[glossary:5-ht2a]] [[glossary:receptor|receptors]] on layer V pyramidal [[glossary:neuron|neurons]] in the [[glossary:cortex]]. Neuroimaging studies demonstrate decreased [[glossary:default-mode-network]] activity — particularly in the posterior cingulate cortex and medial [[glossary:prefrontal-cortex]] — alongside increased frontal and paralimbic [[glossary:activation]]{{cite|doi=10.1371/journal.pone.0118143|anchor=f3f74c7d}}{{cite|doi=10.1007/s00213-006-0358-7|anchor=4f5e1ab1}}. This pattern of disrupted top-down cortical processing is consistent with the REBUS model, in which entrenched cognitive patterns are destabilized and bottom-up sensory flow is enhanced{{flag|citation-needed}}. ===What it changes=== DMT's [[glossary:sigma-1-receptor]] activation contributes neuroprotective and anti-inflammatory effects beyond psychedelia, with roles in cellular bioenergetics and immunoregulation{{cite|doi=10.1007/s00702-013-1024-y|anchor=232dd9b9}}. [[glossary:neuroplasticity]] mechanisms — including [[glossary:bdnf]] [[glossary:upregulation]] and dendritic remodeling — occur after [[substance_class:psychoactive/psychedelic]] administration, with structural changes outlasting the acute experience{{cite|doi=10.3389/fpsyt.2021.724606|anchor=9ecf3f04}}. EEG recordings show alpha-band power suppression in parietal and occipital cortex, correlating with visual imagery [[glossary:intensity]]{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=577b4c43}}. {{DiscoverMore|Open Questions}} Three preparation-specific questions remain unresolved. The pharmacokinetic contribution of tetrahydroharmine's [[substance_class:pharmacological/serotonin-reuptake-inhibitor]] relative to DMT's 5-HT₂A agonism has not been quantified in human studies. No published human pharmacokinetic comparison exists between ''P. viridis'' and ''D. cabrerana'' as admixture substitutions. The role of [[glossary:endogenous]] DMT production (detected in human brain tissue) in modulating the exogenous ayahuasca response remains speculative. {{/DiscoverMore}}

===Where it acts=== Once [[glossary:mao-a]] is inhibited, [[substance:dmt]] enters the brain and activates [[glossary:serotonin]] [[glossary:receptor|receptors]] on [[glossary:neuron|neurons]] in the [[glossary:cortex]]. Neuroimaging shows that this suppresses the [[glossary:default-mode-network]] — the brain [[glossary:circuit]] associated with [[glossary:self-referential-thought]] and rumination — particularly in regions linked to self-[[glossary:awareness]] and planning{{cite|doi=10.1371/journal.pone.0118143|anchor=8e4bc2a2}}{{cite|doi=10.1007/s00213-006-0358-7|anchor=486f6745}}. Frontal and emotional brain regions become more active at the same time. This [[glossary:disruption]] of top-down control, combined with heightened sensory and emotional flow, underlies the [[effect:ego-dissolution]] and introspective [[glossary:intensity]] of the experience{{flag|citation-needed}}. ===What it changes=== DMT's action at [[glossary:sigma-1-receptor|sigma-1 receptors]] contributes anti-inflammatory and neuroprotective effects independent of its [[substance_class:psychoactive/psychedelic]] action{{cite|doi=10.1007/s00702-013-1024-y|anchor=5ec8e161}}. After the experience, proteins involved in neuronal growth and rewiring are elevated, and structural brain changes may persist well beyond the acute state{{cite|doi=10.3389/fpsyt.2021.724606|anchor=c192b22c}}. EEG recordings show reduced alpha-wave activity in visual brain regions during the experience, correlating with the intensity of visual imagery{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=8dbc59dc}}. {{DiscoverMore|Open Questions}} Three preparation-specific questions remain unresolved. The contribution of tetrahydroharmine's [[substance_class:pharmacological/serotonin-reuptake-inhibitor]] relative to DMT's serotonin [[glossary:receptor-activation]] has not been quantified in human studies. No published human pharmacokinetic comparison exists between ''P. viridis'' and ''D. cabrerana'' as admixture substitutions. The role of [[glossary:endogenous]] DMT production — detected in human brain tissue — in modulating the exogenous ayahuasca response remains speculative. {{/DiscoverMore}}

Ayahuasca produces a deeply introspective [[substance_class:psychoactive/psychedelic]] state in which the body is as involved as the mind. [[effect:nausea]] and purging are central features, not incidental ones. Visual imagery can be vivid and complex; emotional material — memories, grief, fear — surfaces and is processed with unusual [[glossary:intensity]]. Effects build over 20–60 minutes, peak at 1.5–2.5 hours, and resolve over 4–8 hours. Brew composition varies widely between batches, and [[glossary:set-and-setting]] exert unusually strong influence on the character of the experience. The experience overlaps most closely with high-dose psilocybin — comparable duration, similar visual complexity, and shared [[effect:ego-dissolution|ego-dissolution]] [[glossary:phenomenology]]. Ayahuasca is consistently distinguished by substantially greater gastrointestinal engagement and a more pronounced emotional-cathartic quality that users and researchers describe as qualitatively distinct from the psilocybin experience.

Ayahuasca produces a deeply introspective [[substance_class:psychoactive/psychedelic]] state in which somatic engagement — [[effect:nausea]], purging, and visceral body sensations — is as central to the experience as visual or cognitive changes. The brew's variable composition means two servings from the same ceremony may deliver substantially different alkaloid loads, and [[glossary:set-and-setting]] exert unusually strong [[glossary:modulation]] on experiential character. Effects build gradually over 20–60 minutes, peak at 1.5–2.5 hours, and resolve over 4–8 hours. The experiential profile overlaps most closely with high-dose psilocybin — comparable duration, similar visual complexity, and shared [[effect:ego-dissolution|ego-dissolution]] [[glossary:phenomenology]] — but with substantially greater gastrointestinal [[glossary:distress]] and a qualitatively distinct emotional-cathartic character that users and researchers consistently distinguish from the psilocybin experience.

===Traditional aqueous decoction=== The traditional preparation — and the form used in virtually all published clinical research — is a concentrated aqueous decoction of ''B. caapi'' vine and ''P. viridis'' leaves. Preparation involves prolonged boiling (typically 4–12 hours), straining, and repeated extraction cycles, with the final liquid reduced to a concentrated volume. '''Traditional decoction (oral):''' No standardized dose tiers (threshold/light/common/strong/heavy) are available from published primary sources for this preparation. Ceremonial doses vary widely across traditions, preparers, and brew [[glossary:potency]]. Clinical research doses provide the best-characterized reference points: 0.6 mg [[substance:dmt]]/kg (low research dose) and 0.85–1.0 mg DMT/kg (moderate to high research dose), equivalent to approximately 42–70 mg DMT in a 70 kg adult{{cite|pubmed=12660312|anchor=704ae3d6}}{{cite|doi=10.1097/JCP.0b013e31823607f6|anchor=63880777}}. Typical ceremonial serving volume is 100–200 mL, delivering approximately 25–100 mg DMT depending on brew concentration{{cite|pubmed=16149328|anchor=cc347f7e}}. Onset: 20–60 minutes. [[glossary:peak]] effects: 1.5–2.5 hours. Total duration: 4–8 hours{{cite|doi=10.1017/S109285292400213X|anchor=ce46aa88}}{{cite|pubmed=12660312|anchor=9aa1a745}}{{cite|doi=10.1016/j.biopha.2025.117908|anchor=0b1eba26}}. [[effect:nausea]] and [[effect:vomiting]] are common, particularly within the first 60 minutes. Cardiovascular effects include mild [[glossary:tachycardia]] and diastolic [[glossary:blood-pressure]] [[glossary:elevation]] of approximately 9 mmHg at 0.85 mg DMT/kg{{cite|pubmed=12660312|anchor=acfbabf8}}. The overall experience encompasses complex visual [[glossary:hallucination|hallucinations]], introspective and emotionally cathartic states, [[effect:ego-dissolution]], and — at higher serum DMT concentrations — [[effect:entity-contact|entity encounters]] and visionary narratives{{cite|doi=10.1162/jocn_a_02003|anchor=00ab6036}}{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=ef2f3b89}}. Potency varies significantly across preparations: analyzed brews show DMT concentrations ranging from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=d2e62794}}{{cite|doi=10.1016/j.jchromb.2019.06.014|anchor=5b1acd6e}}. Re-dosing during ceremonies is common; conservative initial dosing with 60–90 minutes before re-dosing is standard in [[index:harm-reduction|harm reduction]] frameworks. See the Dose by preparation card for structured dose and timing data. ===Pharmahuasca (encapsulated)=== '''Pharmahuasca''' refers to oral capsules containing purified DMT combined with [[substance:harmine]] or harmala alkaloid extract — a standardized [[glossary:structural-analog]] of the traditional brew. Perkins and colleagues administered botanically-derived encapsulated DMT with harmala alkaloids in a Phase 1 study (9 volunteers, 17 dosing sessions), observing strong positive correlations between total dose and Mystical Experience Questionnaire (MEQ) scores, with subjective [[glossary:intensity]] exceeding most naturalistic study findings{{cite|doi=10.1038/s41598-025-25767-x|anchor=314641dd}}. '''Pharmahuasca (oral capsule):''' Onset: 30–60 minutes. Duration: 4–5 hours. The standardized alkaloid content reduces the inter-dose variability inherent to traditional brews but does not eliminate individual pharmacokinetic variation. ===Buccal and transmucosal formulation (research)=== A novel transmucosal delivery system has been characterized in controlled studies. Buccal co-administration of DMT and harmine in 16 healthy participants achieved DMT cmax of 33 ng/mL and harmine cmax of 49 ng/mL, with harmine markedly enhancing DMT [[glossary:bioavailability]]{{cite|doi=10.1016/j.biopha.2025.117908|anchor=0d9cb270}}{{cite|doi=10.1016/j.biopha.2025.118329|anchor=2b3f73a2}}. Duration: 4–5 hours. Nausea, vomiting, and intense hallucinations were noted as [[glossary:adverse-effects]] associated with the complex pharmacokinetic and [[glossary:pharmacodynamic-interaction|pharmacodynamic interactions]] of the combined formulation{{cite|doi=10.1093/ijnp/pyaf001|anchor=470ede50}}. This formulation remains investigational and is not available outside research settings. ===Anahuasca (botanical analogs)=== '''Anahuasca''' preparations use alternative botanical sources with equivalent pharmacological profiles — for example, ''Mimosa hostilis'' root bark as a DMT source and ''Peganum harmala'' (Syrian rue) seeds as a beta-carboline source. No published controlled human pharmacokinetic studies compare anahuasca formulations to traditional ''B. caapi'' and ''P. viridis'' brews. Dose [[glossary:inference|extrapolation]] between preparations is unreliable due to differences in alkaloid ratios and extraction efficiency.

====Traditional decoction (oral)==== '''Traditional decoction''' is the standard preparation. Sections of ''B. caapi'' vine are pounded and boiled with ''P. viridis'' leaves (or ''D. cabrerana'') through multiple reduction cycles, producing a dark, viscous liquid consumed orally. In controlled studies at doses of 0.6–0.85 mg [[substance:dmt]]/kg body weight, onset occurs at 20–60 minutes, peak at 1.5–2.5 hours, and total duration is 4–8 hours{{cite|doi=10.1017/S109285292400213X|anchor=cac48f62}}{{cite|pubmed=12660312|anchor=f7446f80}}. Inter-batch DMT concentration varies from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=33b915ab}} — a "standard dose" cannot be established without analytical testing. ====Ceremonial preparations (variable admixtures)==== '''Ceremonial preparations''' may include additional botanicals beyond the core vine-and-leaf combination. Tobacco (''Nicotiana rustica''), ''Brugmansia'', or ''Datura'' species are added in some traditions. Plants containing [[substance_class:chemical/tropane]] alkaloids ([[substance:scopolamine]], atropine) create anticholinergic [[glossary:toxicity]] risk mechanistically separate from ayahuasca's serotonergic effects. Composition is typically not disclosed to participants in advance. ====Freeze-dried and encapsulated (oral)==== '''Freeze-dried ayahuasca''' and encapsulated preparations are used in some research and retreat settings. These aim for more consistent dosing but remain unstandardized — no accredited quality control framework exists, and alkaloid content still varies between batches. Onset and duration are comparable to traditional decoction. ====Buccal and transmucosal (research formulation)==== '''Buccal co-administration''' of DMT and [[substance:harmine]] has been investigated in clinical research. This route achieves higher peak DMT concentrations than oral decoction, with harmine markedly increasing DMT [[glossary:bioavailability]]{{cite|doi=10.1016/j.biopha.2025.117908|anchor=c465192f}}{{cite|doi=10.1016/j.biopha.2025.118329|anchor=c499ea42}}. Duration is approximately 4–5 hours. This formulation remains experimental. Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

====Toxicity==== A [[glossary:systematic-review]] of 78 articles concluded that ayahuasca is generally safe in healthy populations under controlled conditions, with serious [[glossary:adverse-events]] rarely reported{{cite|doi=10.1177/10915818241230916|anchor=82e9ce3c}}. No published [[glossary:case-report|case reports]] of death attributable solely to traditional ayahuasca consumed without concurrent [[glossary:serotonergic-drug|serotonergic drugs]] were identified in the peer-reviewed literature. Moderate [[glossary:sympathomimetic]] cardiovascular effects are documented: diastolic [[glossary:blood-pressure]] increase of approximately 9 mmHg at 0.85 mg [[substance:dmt]]/kg, [[glossary:tachycardia]], and prolactin and cortisol [[glossary:elevation]]{{cite|pubmed=12660312|anchor=58609325}}{{cite|doi=10.1097/JCP.0b013e31823607f6|anchor=f9c5f915}}. Developmental [[glossary:toxicity]] has been demonstrated in rats: at 4× and 8× human equivalent doses administered during gestation, maternal mortality reached 44–52% with kidney injury; the 2× dose produced neuronal loss in [[glossary:hippocampus|hippocampal]] CA1 region{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=79a9c907}}. These data establish [[glossary:pregnancy]] as a [[glossary:contraindication]]. '''Contaminant and adulterant risk:''' Ayahuasca preparations are subject to multiple contamination vectors. No standardized quality control exists — alkaloid content varies from 0.05 to 14.2 mg/mL between batches{{cite|pubmed=16149328|anchor=4ce77e23}}. Ceremonial preparations may include undisclosed admixture plants, notably ''Brugmansia'' or ''Datura'' species containing [[substance_class:chemical/tropane]] alkaloids ([[substance:scopolamine]], atropine), creating anticholinergic [[glossary:toxidrome]] risk. Aqueous decoctions stored improperly can support microbial growth. Commercial preparations sold through retreat operations or online sources may contain misrepresented [[glossary:potency]] or non-botanical adulterants. No ISO/IEC-accredited testing framework or Certificate of Analysis standard exists for ayahuasca. Ehrlich reagent confirms presence of [[substance_class:chemical/indole-alkaloid|indole alkaloids]] but does not quantify concentration or detect non-[[substance_class:chemical/indole]] adulterants. ====Psychological Risks==== Acute psychological [[glossary:adverse-effects]] include [[effect:anxiety]], fear, [[effect:paranoia]], [[effect:confusion]], perceptual overwhelm, and transient psychotic-like symptoms. [[glossary:intensity]] correlates with peak DMT serum concentration{{cite|doi=10.1162/jocn_a_02003|anchor=a5c6dbb2}}. A systematic review documented that a subset of naturalistic users from retreat settings experienced persistent psychiatric complications including anxiety, depressive episodes, and [[effect:thought-disorganization]]{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=9db075da}}. [[glossary:psychosis]] precipitation is a risk in individuals with personal or family history of psychotic [[glossary:disorder|disorders]]. Ceremonial contexts with experienced facilitators are associated with lower acute adverse event rates in observational data{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=ee6617d0}}. Post-session psychotherapeutic [[glossary:integration]] is supported by observational evidence for reducing adverse psychological sequelae{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=2ff25c67}}. ====Tolerance & Dependence==== No behavioral [[glossary:tolerance]] development across sessions has been documented in regular ritual users{{cite|doi=10.1017/S109285292400213X|anchor=0509081a}}{{cite|doi=10.3390/ph13110334|anchor=643eaca7}}. No physical dependence or characteristic [[glossary:withdrawal]] has been documented{{cite|doi=10.1080/02791072.2016.1188225|anchor=ac7a2ad5}}{{cite|doi=10.3390/ph13110334|anchor=d16922aa}}. Anti-addictive properties are suggested by the evidence: a systematic review found that 4 of 5 human observational studies showed reductions in substance [[glossary:dependence]] symptoms among ayahuasca users{{cite|doi=10.1080/02791072.2016.1188225|anchor=6a123aa8}}. Long-term cognitive safety has been assessed in a cross-sectional study (n=48) of religious users with over 20 years of regular use: no cognitive decline was detected{{cite|doi=10.1007/s00406-024-01817-9|anchor=2246f31a}}. ====Drug Interactions==== The reversible MAO-A [[glossary:inhibition]] from beta-carboline alkaloids creates the primary interaction hazard. Co-administration with serotonergic drugs within the MAO-A inhibition window carries risk of '''serotonin syndrome''' — a potentially fatal condition characterized by [[glossary:hyperthermia]], neuromuscular [[glossary:muscle-rigidity|rigidity]], autonomic instability, and altered mental status. '''SSRIs and SNRIs:''' Fluoxetine and paroxetine are strong [[glossary:cyp2d6]] [[glossary:inhibitor|inhibitors]]; modeling predicts they significantly increase both DMT and [[substance:harmine]] [[glossary:plasma-concentration|plasma exposure]]{{cite|doi=10.3389/fmolb.2026.1768402|anchor=988d7c1a}}. The pharmacodynamic risk ([[glossary:serotonin]] [[glossary:accumulation]]) compounds the pharmacokinetic risk (elevated DMT and harmine from CYP2D6 inhibition). Minimum washout: 2 weeks from most SSRIs and SNRIs; 5 weeks for fluoxetine due to the long [[glossary:half-life]] of norfluoxetine. '''Irreversible MAOIs (phenelzine, tranylcypromine):''' Additive MAO-A inhibition with high [[glossary:serotonin-syndrome]] risk. '''Tramadol:''' Combined serotonergic [[glossary:potentiation]] and CYP2D6 interaction; [[effect:seizure-threshold-reduction]]. '''Lithium:''' [[glossary:seizure]] risk noted in [[index:harm-reduction|harm reduction]] literature with mechanistic plausibility{{flag|safety-citation-needed}}. '''Stimulants (amphetamines, cocaine):''' Additive sympathomimetic and serotonergic effects; compounded cardiovascular risk. '''Antipsychotics:''' Pharmacodynamic [[glossary:antagonism]] at [[glossary:5-ht2a]] may blunt effects; QTc prolongation risk with concurrent use. ====Contraindications==== '''Absolute contraindications:''' * '''Concurrent serotonergic medication''' (SSRIs, SNRIs, MAOIs, [[substance:tramadol]]): serotonin syndrome risk via pharmacokinetic and pharmacodynamic mechanisms{{cite|doi=10.3389/fmolb.2026.1768402|anchor=71d17bcb}}. * '''Pregnancy:''' Developmental toxicity demonstrated in rats — neuronal loss at 2× human equivalent dose; embryolethality at 8× dose{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=7f074029}}. * '''Active psychotic disorders''' or personal/family history of schizophrenia or schizotypal personality disorder. '''Relative contraindications:''' * '''Severe cardiovascular disease:''' Sympathomimetic effects include tachycardia and diastolic blood pressure elevation of approximately 9 mmHg at 0.85 mg DMT/kg{{cite|pubmed=12660312|anchor=ac2ce575}}. * '''Acute bipolar disorder:''' [[effect:mania]] risk mechanistically plausible given serotonergic [[glossary:activation]]. * '''Severe hepatic impairment:''' Harmine [[glossary:metabolism]] depends on CYP2D6 and CYP1A2; impaired [[glossary:clearance]] may prolong MAO-A inhibition{{flag|safety-citation-needed}}. * '''Lithium therapy:''' Seizure risk{{flag|safety-citation-needed}}.

====Traditional decoction (oral)==== '''Traditional decoction''' is the standard preparation: sections of ''B. caapi'' vine are pounded and boiled with ''P. viridis'' leaves (or ''D. cabrerana'') in water for several hours, often through multiple reduction cycles. The resulting dark, viscous liquid is consumed orally. In controlled studies at doses of 0.6–0.85 mg [[substance:dmt]]/kg body weight, onset occurs at 20–60 minutes, peak effects at 1.5–2.5 hours, with total duration of 4–8 hours{{cite|doi=10.1017/S109285292400213X|anchor=990030dc}}{{cite|pubmed=12660312|anchor=51594660}}. Inter-batch DMT concentration varies from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=7f00bbf2}}, making a "standard dose" impossible to define without analytical testing. ====Ceremonial preparations (variable admixtures)==== '''Ceremonial preparations''' may include additional botanicals beyond the core vine-and-leaf combination. Tobacco (''Nicotiana rustica''), ''Brugmansia'', or ''Datura'' species are added in some traditions, significantly altering the pharmacological and safety profile. Addition of [[substance_class:chemical/tropane]]-alkaloid-containing plants creates anticholinergic [[glossary:toxicity]] risk mechanistically distinct from ayahuasca's serotonergic effects. Composition is typically not disclosed to participants in advance. ====Freeze-dried and encapsulated (oral)==== '''Freeze-dried ayahuasca''' and encapsulated preparations are used in some research and retreat settings. These aim for more consistent dosing but remain unstandardized — no ISO-accredited quality control framework exists, and alkaloid content varies between batches. Onset and duration are comparable to traditional decoction. ====Buccal and transmucosal (research formulation)==== '''Buccal co-administration''' of DMT and [[substance:harmine]] has been investigated in clinical research. In 16 healthy participants, this route achieved higher peak DMT concentrations than oral decoction, with harmine markedly enhancing DMT [[glossary:bioavailability]]{{cite|doi=10.1016/j.biopha.2025.117908|anchor=5f58c992}}{{cite|doi=10.1016/j.biopha.2025.118329|anchor=753caf09}}. Duration is approximately 4–5 hours. This formulation remains experimental. Per-preparation dose tiers, timelines, and bioavailability data are in the Dose · by preparation card on this page.

====Toxicity==== A [[glossary:systematic-review]] of 78 articles concluded that ayahuasca is generally safe in healthy populations under controlled conditions, with serious [[glossary:adverse-events]] rarely reported{{cite|doi=10.1177/10915818241230916|anchor=48dd76bf}}. No published [[glossary:case-report|case reports]] of death attributable solely to traditional ayahuasca without concurrent [[glossary:serotonergic-drug|serotonergic drugs]] were identified in the peer-reviewed literature. Moderate cardiovascular effects occur: diastolic [[glossary:blood-pressure]] rises approximately 9 mmHg at 0.85 mg [[substance:dmt]]/kg, accompanied by elevated [[glossary:heart-rate]], prolactin, and cortisol{{cite|pubmed=12660312|anchor=9e455680}}{{cite|doi=10.1097/JCP.0b013e31823607f6|anchor=48a5f832}}. [[glossary:animal-model|Animal studies]] show developmental [[glossary:toxicity]]: at twice the human equivalent dose during gestation, neuronal loss occurs in the [[glossary:hippocampus]]; at four to eight times the human equivalent dose, maternal [[glossary:mortality]] reached 44–52%{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=b124e632}}. [[glossary:pregnancy]] is an absolute [[glossary:contraindication]]. '''Contaminant and adulterant risk:''' No standardized quality control exists — alkaloid content varies from 0.05 to 14.2 mg/mL between analyzed batches{{cite|pubmed=16149328|anchor=3974668f}}. Some ceremonial preparations include undisclosed ''Brugmansia'' or ''Datura'' containing [[substance_class:chemical/tropane]] alkaloids ([[substance:scopolamine]], atropine), creating anticholinergic toxicity risk on top of the serotonergic effects. Ehrlich reagent confirms the presence of [[substance_class:chemical/indole-alkaloid|indole alkaloids]] but does not quantify concentration or detect non-[[substance_class:chemical/indole]] [[glossary:adulterant|adulterants]]. ====Psychological Risks==== Acute [[glossary:adverse-effects]] include [[effect:anxiety]], fear, [[effect:paranoia]], [[effect:confusion]], perceptual overwhelm, and brief psychotic-like symptoms — [[glossary:intensity]] correlates with peak DMT concentration{{cite|doi=10.1162/jocn_a_02003|anchor=0c551106}}. A systematic review found that a subset of retreat users developed persistent anxiety, depressive episodes, or [[effect:thought-disorganization]]{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=8f12e884}}. Individuals with a personal or family history of psychotic [[glossary:disorder|disorders]] carry meaningful risk of [[glossary:psychosis]] precipitation. Experienced facilitation is associated with lower adverse event rates{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=4546c14b}}. ====Tolerance & Dependence==== No [[glossary:tolerance]] development across sessions has been documented in regular ritual users{{cite|doi=10.1017/S109285292400213X|anchor=fa945979}}{{cite|doi=10.3390/ph13110334|anchor=08e5a80f}}. No [[glossary:physical-dependence]] or [[glossary:withdrawal]] has been documented{{cite|doi=10.1080/02791072.2016.1188225|anchor=c489f04a}}{{cite|doi=10.3390/ph13110334|anchor=8d839e32}}. Observational data suggest the opposite pattern: a systematic review found that 4 of 5 human studies showed reductions in substance [[glossary:dependence]] symptoms among ayahuasca users{{cite|doi=10.1080/02791072.2016.1188225|anchor=0b1a3bec}}. A cross-sectional study of 48 long-term religious users with over 20 years of regular use found no cognitive decline{{cite|doi=10.1007/s00406-024-01817-9|anchor=a922178d}}. ====Drug Interactions==== The beta-carboline alkaloids inhibit [[glossary:mao-a]] for several hours after consumption. Combining ayahuasca with serotonergic drugs during this window risks '''serotonin syndrome''' — a potentially fatal condition involving overheating, rigid muscles, unstable heart rate, and altered mental status. SSRIs and SNRIs raise this risk through two mechanisms: serotonergic [[glossary:accumulation]], and elevated DMT and [[substance:harmine]] blood levels, because fluoxetine and paroxetine also block [[glossary:cyp2d6]], the [[glossary:enzyme]] that clears these alkaloids{{cite|doi=10.3389/fmolb.2026.1768402|anchor=ed43f534}}. Minimum washout: 2 weeks for most SSRIs and SNRIs; 5 weeks for fluoxetine. * '''Irreversible MAOIs (phenelzine, tranylcypromine):''' additive MAO-A [[glossary:inhibition]]; high [[glossary:serotonin-syndrome]] risk. * '''Tramadol:''' combined serotonergic [[glossary:potentiation]] and CYP2D6 interaction; [[effect:seizure-threshold-reduction]]. * '''Lithium:''' [[glossary:seizure]] risk noted in [[index:harm-reduction|harm reduction]] literature{{flag|safety-citation-needed}}. * '''Stimulants (amphetamines, cocaine):''' additive [[glossary:sympathomimetic]] and serotonergic effects; compounded cardiovascular risk. * '''Antipsychotics:''' may blunt [[substance_class:psychoactive/psychedelic]] effects at [[glossary:5-ht2a]]; QTc prolongation risk with concurrent use. ====Contraindications==== '''Absolute contraindications:''' * '''Concurrent serotonergic medication''' (SSRIs, SNRIs, MAOIs, [[substance:tramadol]]): serotonin syndrome risk via pharmacokinetic and pharmacodynamic mechanisms{{cite|doi=10.3389/fmolb.2026.1768402|anchor=a29036e0}}. * '''Pregnancy:''' developmental toxicity demonstrated in rats — neuronal loss at 2× human equivalent dose; embryolethality at 8× dose{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=daca4258}}. * '''Active psychotic disorders''' or personal/family history of schizophrenia or schizotypal personality disorder. '''Relative contraindications:''' * '''Severe cardiovascular disease:''' sympathomimetic effects include [[glossary:tachycardia]] and approximately 9 mmHg diastolic blood pressure [[glossary:elevation]] at 0.85 mg DMT/kg{{cite|pubmed=12660312|anchor=3106e1c1}}. * '''Acute bipolar disorder:''' [[effect:mania]] risk mechanistically plausible given serotonergic [[glossary:activation]]. * '''Severe hepatic impairment:''' impaired harmine [[glossary:clearance]] may prolong MAO-A inhibition{{flag|safety-citation-needed}}. * '''Lithium therapy:''' seizure risk{{flag|safety-citation-needed}}.

===Forms & Identification=== Ayahuasca is encountered as a dark brown to reddish-brown viscous liquid with a strongly bitter, astringent taste. Color and viscosity vary with brewing method and concentration. Ehrlich [[glossary:reagent-kit|reagent testing]] confirms the presence of [[substance_class:chemical/indole-alkaloid|indole alkaloids]] ([[substance:dmt]] and beta-carbolines produce a purple color change) but provides no quantitative information. Given the 280-fold variation in DMT concentration documented across analyzed preparations, laboratory-verified alkaloid content is the only basis for informed dosing decisions. ===Set & Setting=== Ayahuasca's extended duration (4–8 hours), intense emotional content, and prominent physical effects make environment and preparation critical. A comfortable, private space with easy bathroom access is essential. Experienced facilitation — whether ceremonial or clinical — is associated with lower adverse event rates in observational data. First-time use should be accompanied by a sober, [[glossary:sitter|trusted companion]] throughout. The experience frequently involves emotionally challenging material; psychological readiness and clear intention reduce — but do not eliminate — the likelihood of distressing episodes. {{Guideline}} ===Guidelines=== * Start with a low dose, particularly with an unfamiliar brew — [[glossary:potency]] varies dramatically between preparations. * Ensure adequate [[glossary:hydration]] before and during the experience. Have water and electrolytes available. * Fast for at least 4–6 hours before consumption to reduce [[effect:nausea]] [[glossary:intensity]] and improve [[glossary:absorption]] consistency. * Prepare towels, buckets, and a clear path to a bathroom — purging is expected, not exceptional. * Have a sober sitter or experienced facilitator present throughout. * Avoid [[glossary:redose|redosing]] within the first 90 minutes — onset can be delayed, and premature redosing risks overshooting. * Plan for a full recovery day afterward — do not drive or operate machinery for at least 12 hours post-[[glossary:ingestion]]. * Verify [[glossary:medication]] status: discontinue SSRIs, SNRIs, and [[substance:tramadol]] with appropriate washout periods before use. Consult a physician before stopping any prescribed medication. {{/Guideline}} {{Emergency}} ===Emergency Response=== '''Recognizing an emergency:''' * Sustained rigid muscles, high fever, or profuse sweating — suspect '''serotonin syndrome''' * [[glossary:seizure|Seizures]] or unresponsiveness * Severe [[effect:confusion]] or [[glossary:agitation]] lasting more than 30 minutes beyond the expected peak * [[glossary:chest-pain]], difficulty breathing, or irregular heartbeat * [[glossary:psychosis|Psychotic symptoms]] (persistent [[effect:delusions]], violent agitation) unresponsive to verbal [[glossary:reassurance]] '''Immediate steps:''' * Do not leave the person alone. * If [[glossary:serotonin-syndrome]] is suspected ([[glossary:muscle-rigidity|rigidity]], [[glossary:hyperthermia]], [[glossary:clonus]]), call emergency services immediately — this is life-threatening. * Move the person to a cool, quiet area. Remove excess clothing if hyperthermic. * Place an unresponsive person in the [[glossary:recovery-position]] to protect the [[glossary:airway]] during [[effect:vomiting]]. * Do not attempt to restrain someone experiencing agitation; create space and remove hazards. '''What to tell the dispatcher:''' Name the substance (ayahuasca — containing DMT and [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]]), approximate time of ingestion, quantity if known, all symptoms observed, and any medications the person takes. [[glossary:good-samaritan-law|Good Samaritan laws]] providing legal protection for reporting drug emergencies exist in many jurisdictions. No reversal agent for ayahuasca exists. Treatment is supportive. Hospital intervention may include [[substance_class:chemical/benzodiazepine|benzodiazepines]] for agitation and cyproheptadine for serotonin syndrome. {{/Emergency}} {{Aftercare}} ===Aftercare & Integration=== The hours and days following an ayahuasca experience are characterized by emotional [[glossary:sensitivity]], [[glossary:fatigue]], and altered perspective. Eat lightly after the experience — bland foods, broth, and fruit are well-tolerated. Rehydrate thoroughly, particularly after significant purging. Many users report heightened emotional processing in the 1–3 days afterward. Journaling and quiet reflection support [[glossary:integration]]. Avoid major life decisions in the immediate aftermath — [[glossary:insight|insights]] benefit from sober re-evaluation. Post-session psychotherapeutic integration — discussing the experience with a trained professional — is supported by observational evidence for reducing adverse psychological outcomes. If distressing thoughts, [[effect:anxiety]], or [[effect:depersonalization]] persist beyond 72 hours, seek professional support promptly. {{/Aftercare}} {{Recovery}} ===Recovery & Support=== Ayahuasca does not produce [[glossary:physical-dependence]], and formal cessation protocols are not typically required. However, psychological attachment to repeated ceremonial use can develop. If ayahuasca use is interfering with daily functioning or being used to avoid addressing mental health needs through conventional care, professional support is appropriate. For individuals experiencing persistent psychological [[glossary:distress]] after ayahuasca use — including prolonged anxiety, depersonalization, or trauma re-[[glossary:activation]] — the following resources are available: * '''SAMHSA National Helpline:''' 1-800-662-4357 (free, confidential, 24/7) * '''Fireside Project:''' 62-FIRESIDE (623-473-7433) — [[substance_class:psychoactive/psychedelic]] [[glossary:peer-support]] line * '''Crisis Text Line:''' Text HOME to 741741 For psychiatric emergencies, call emergency services or go to the nearest emergency department. {{/Recovery}}

===Forms & Identification=== Ayahuasca is primarily encountered as a dark brown to reddish-brown viscous liquid with a strongly bitter, astringent taste. Color and viscosity vary with brewing method and concentration. Laboratory testing is the only reliable way to determine alkaloid content — visual inspection and taste cannot distinguish a weak brew from a concentrated one. Ehrlich [[glossary:reagent-kit|reagent testing]] confirms the presence of [[substance_class:chemical/indole-alkaloid|indole alkaloids]] ([[substance:dmt]] and beta-carbolines produce a purple color change) but provides no quantitative information. Given the 280-fold variation in DMT concentration documented across analyzed preparations, lab-verified alkaloid content is the only basis for informed dosing decisions. ===Set & Setting=== Ayahuasca's extended duration (4–8 hours), intense emotional content, and prominent physical effects ([[effect:nausea]], purging) make environment and preparation critical. A comfortable, private space with easy bathroom access is essential. Experienced facilitation — whether ceremonial or clinical — is associated with lower adverse event rates in observational data. First-time users should be accompanied by a sober, [[glossary:sitter|trusted companion]]. The experience frequently involves emotionally challenging material; psychological readiness and clear intention reduce — but do not eliminate — the likelihood of distressing episodes. {{Guideline}} ===Guidelines=== * Start with a low dose, particularly with an unfamiliar brew — [[glossary:potency]] varies dramatically between preparations. * Ensure adequate [[glossary:hydration]] before and during the experience. Have water and electrolytes available. * Fast for at least 4–6 hours before consumption to reduce nausea [[glossary:intensity]] and improve [[glossary:absorption]] consistency. * Prepare towels, buckets, and a clear path to a bathroom — purging is expected, not exceptional. * Have a sober sitter or experienced facilitator present throughout. * Avoid [[glossary:redose|redosing]] within the first 90 minutes — onset can be delayed, and premature redosing risks overshooting. * Plan for a full recovery day afterward — do not drive or operate machinery for at least 12 hours post-[[glossary:ingestion]]. * Verify [[glossary:medication]] status: discontinue SSRIs, SNRIs, and [[substance:tramadol]] with appropriate washout periods before use. Consult a physician before stopping any prescribed medication. {{/Guideline}} {{Emergency}} ===Emergency Response=== '''Recognizing an emergency:''' * Sustained rigid muscles, high fever, or profuse sweating — suspect '''serotonin syndrome''' * [[glossary:seizure|Seizures]] or unresponsiveness * Severe [[effect:confusion]] or [[glossary:agitation]] lasting more than 30 minutes beyond the expected peak * [[glossary:chest-pain]], difficulty breathing, or irregular heartbeat * [[glossary:psychosis|Psychotic symptoms]] (persistent [[effect:delusions]], violent agitation) unresponsive to verbal [[glossary:reassurance]] '''Immediate steps:''' * Do not leave the person alone. * If [[glossary:serotonin-syndrome]] is suspected ([[glossary:muscle-rigidity|rigidity]], [[glossary:hyperthermia]], [[glossary:clonus]]), call emergency services immediately — this is life-threatening. * Move the person to a cool, quiet area. Remove excess clothing if hyperthermic. * Place an unresponsive person in the [[glossary:recovery-position]] to protect the [[glossary:airway]] during [[effect:vomiting]]. * Do not attempt to restrain someone experiencing agitation; create space and remove hazards. '''What to tell the dispatcher:''' Name the substance (ayahuasca — containing DMT and [[substance_class:pharmacological/monoamine-oxidase-inhibitor|monoamine oxidase inhibitors]]), approximate time of ingestion, quantity if known, all symptoms observed, and any medications the person takes. [[glossary:good-samaritan-law|Good Samaritan laws]] providing legal protection for reporting drug emergencies exist in many jurisdictions. No reversal agent for ayahuasca exists. Treatment is supportive. Hospital intervention may include [[substance_class:chemical/benzodiazepine|benzodiazepines]] for agitation and cyproheptadine for serotonin syndrome. {{/Emergency}} {{Aftercare}} ===Aftercare & Integration=== The hours and days following an ayahuasca experience are characterized by emotional [[glossary:sensitivity]], [[glossary:fatigue]], and altered perspective. Eat lightly after the experience — bland foods, broth, and fruit are well-tolerated. Rehydrate thoroughly, particularly after significant purging. Many users report heightened emotional processing in the 1–3 days afterward. Journaling and quiet reflection support [[glossary:integration]]. Avoid major life decisions in the immediate aftermath — [[glossary:insight|insights]] benefit from sober re-evaluation. Post-session psychotherapeutic integration — discussing the experience with a trained professional — is supported by observational evidence for reducing adverse psychological outcomes. If distressing thoughts, [[effect:anxiety]], or [[effect:depersonalization]] persist beyond 72 hours, seek professional support promptly. {{/Aftercare}} {{Recovery}} ===Recovery & Support=== Ayahuasca does not produce [[glossary:physical-dependence]], and formal cessation protocols are not typically required. However, psychological attachment to repeated ceremonial use can develop. If ayahuasca use is interfering with daily functioning or being used to avoid addressing mental health needs through conventional care, professional support is appropriate. For individuals experiencing persistent psychological [[glossary:distress]] after ayahuasca use — including prolonged anxiety, depersonalization, or trauma re-[[glossary:activation]] — the following resources are available: * '''SAMHSA National Helpline:''' 1-800-662-4357 (free, confidential, 24/7) * '''Fireside Project:''' 62-FIRESIDE (623-473-7433) — [[substance_class:psychoactive/psychedelic]] [[glossary:peer-support]] line * '''Crisis Text Line:''' Text HOME to 741741 If you are experiencing a psychiatric emergency, contact emergency services or go to your nearest emergency department. {{/Recovery}}

[[substance:dmt]] is [[glossary:schedule-i]] under the 1971 United Nations [[glossary:convention-on-psychotropic-substances]]. However, the UN treaties do not schedule the plants themselves — ''Banisteriopsis caapi'' and ''Psychotria viridis'' are not listed in the 1961, 1971, or 1988 [[glossary:drug-control|drug control conventions]]{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=2d556460}}. This creates divergent national approaches: some countries treat ayahuasca brews as illegal DMT preparations, while others carve out explicit protections for religious or traditional ceremonial use. In the United States, ayahuasca is federally illegal under Schedule I, though two religious organizations — União do Vegetal (upheld by Supreme Court in 2006) and Santo Daime — hold court-protected exemptions under the Religious Freedom Restoration Act. Brazil authorized religious and ceremonial use in 1987; Peru recognizes traditional ceremonial use as national cultural heritage. The United Kingdom, the Netherlands, and Germany prohibit it due to DMT content, with no religious exemptions. Canada classifies DMT as [[glossary:schedule-iii]]. Standard urine drug screens do not detect DMT or beta-carboline alkaloids — [[glossary:detection]] requires specialized [[glossary:laboratory-analysis]], and in one study of religious users, DMT and beta-carbolines were detectable in saliva and serum for approximately 24 hours post-[[glossary:ingestion]]{{cite|doi=10.1002/dta.2955|anchor=1db990c4}}. {{Warning}} Legal status changes frequently. This overview reflects the status as of the article's last update and is not legal advice. Verify current law in the relevant jurisdiction before acting on this information. {{/Warning}}

===Primary receptor targets=== [[substance:dmt]] acts as a [[glossary:partial-agonist]] at [[glossary:5-ht2a]] [[glossary:receptor|receptors]] — the principal mediator of its [[substance_class:psychoactive/psychedelic]] effects, confirmed by ketanserin [[glossary:blockade]] in human subjects{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=dbb281b7}}. Additional receptor activity includes partial agonism at [[glossary:5-ht1a]] and [[glossary:5-ht2c]] receptors{{cite|doi=10.1017/S109285292400213X|anchor=82fef3da}}{{cite|doi=10.1007/s00018-024-05353-6|anchor=7d0556de}}, agonism at [[glossary:taar1]] (TAAR1){{cite|doi=10.3390/biom12111618|anchor=eee5480f}}, and [[glossary:sigma-1-receptor]] (Sig-1R) [[glossary:activation]] at mitochondria-associated membranes — a mechanism implicated in neuroprotection, cellular bioenergetics, and immunoregulation{{cite|doi=10.3389/fphar.2016.00035|anchor=10380e07}}{{cite|doi=10.1007/s00702-013-1024-y|anchor=b594af0a}}. DMT exhibits [[glossary:substrate]] behavior at both the [[glossary:serotonin-transporter]] (SERT; Ki ~4.00 µM) and VMAT2 (VMAT2; Ki ~93 µM), facilitating intraneuronal [[glossary:accumulation]] rather than synaptic [[glossary:reuptake-inhibitor|reuptake blockade]]{{cite|doi=10.1007/s00702-009-0308-8|anchor=a3fbbd42}}. The beta-carbolines [[substance:harmine]], [[substance:harmaline]], and tetrahydroharmine function as reversible, competitive [[glossary:mao-a]] [[glossary:inhibitor|inhibitors]], preventing [[glossary:first-pass-metabolism|first-pass]] oxidative deamination of DMT by intestinal and hepatic MAO-A. Without this [[glossary:inhibition]], oral DMT is approximately 97% metabolized to [[substance_class:chemical/indole]]-3-acetic acid (IAA) and produces no psychotropic effects{{cite|doi=10.1002/dta.1685|anchor=6a787edd}}. Harmine additionally inhibits DYRK1A kinase, the [[glossary:dopamine-transporter]], and [[substance_class:chemical/imidazoline]] receptors{{cite|doi=10.1016/j.pnpbp.2012.06.001|anchor=36ab757a}}. Tetrahydroharmine acts as a weak [[substance_class:pharmacological/serotonin-reuptake-inhibitor]], potentially contributing an [[substance_class:psychoactive/anxiolytic]] or [[substance_class:psychoactive/antidepressant]] component independent of DMT's psychedelic effects{{cite|doi=10.3390/biom12111618|anchor=5379caa0}}. ===CNS mechanism=== Following MAO-A inhibition, DMT crosses the blood–brain barrier and activates 5-HT₂A receptors predominantly on layer V pyramidal [[glossary:neuron|neurons]] in the [[glossary:cortex]]. Neuroimaging studies demonstrate decreased [[glossary:default-mode-network]] (DMN) activity — particularly in the posterior cingulate cortex (PCC)/precuneus and medial [[glossary:prefrontal-cortex]] (mPFC) — alongside increased frontal and paralimbic activation{{cite|doi=10.1371/journal.pone.0118143|anchor=34694fa3}}{{cite|doi=10.1007/s00213-006-0358-7|anchor=adddac4f}}. EEG recordings show alpha-band power suppression in parietal and occipital cortex, correlating with the [[glossary:intensity]] of visual imagery{{cite|doi=10.1016/j.euroneuro.2016.03.012|anchor=0d0e8f59}}. These findings are consistent with disrupted hierarchical predictive processing — the REBUS (relaxed beliefs under psychedelics) model — in which top-down cortical constraints are loosened, enabling enhanced bottom-up sensory information flow and the [[glossary:destabilization]] of entrenched cognitive patterns{{flag|citation-needed}}. Sigma-1 receptor activation by DMT contributes neuroprotective and anti-inflammatory effects beyond serotonergic psychedelia, including roles in cellular bioenergetics and immunoregulation{{cite|doi=10.1007/s00702-013-1024-y|anchor=130dd9e4}}. [[glossary:neuroplasticity]] mechanisms — including [[glossary:bdnf]] [[glossary:upregulation]] and dendritic remodeling — occur after single and repeated psychedelic administration, with structural changes outlasting the acute experience{{cite|doi=10.3389/fpsyt.2021.724606|anchor=fb7cbc72}}. ===Pharmacokinetics=== ====Oral decoction (traditional and research standard)==== In controlled human studies at doses of 0.6–0.85 mg DMT/kg body weight: DMT cmax 12.14–17.44 ng/mL, tmax approximately 1.5 hours{{cite|pubmed=12660312|anchor=f8257aa1}}. Onset occurs at 20–60 minutes, peak [[index:effects|subjective effects]] at 1.5–2.5 hours, with total duration of 4–8 hours{{cite|doi=10.1017/S109285292400213X|anchor=af511290}}{{cite|pubmed=12660312|anchor=888e2bd8}}. [[glossary:peak]] DMT serum concentration — not dose volume consumed — drives the primary phenomenological characteristics, indicating substantial interindividual variation in [[glossary:absorption]] and first-pass metabolism{{cite|doi=10.1162/jocn_a_02003|anchor=aa7a867a}}. ====Buccal and transmucosal (research formulation)==== Buccal co-administration of DMT and harmine in 16 healthy participants achieved DMT [[glossary:cmax]] of 33 ng/mL and harmine Cmax of 49 ng/mL, with harmine markedly enhancing DMT [[glossary:bioavailability]] and prolonging absorption{{cite|doi=10.1016/j.biopha.2025.117908|anchor=54f7a7ec}}{{cite|doi=10.1016/j.biopha.2025.118329|anchor=efb90d1e}}. Duration: 4–5 hours. ===CYP enzyme involvement=== DMT is primarily metabolized by MAO-A when available, with secondary [[glossary:metabolism]] via [[glossary:cyp2d6]] and, to a lesser extent, [[glossary:cyp3a4]]. Harmine and harmaline are substrates of CYP2D6 and [[glossary:cyp1a2]]. Physiologically based pharmacokinetic (PBPK) modeling predicts that CYP2D6 inhibitors — notably fluoxetine and paroxetine — significantly increase both DMT and harmine [[glossary:plasma-concentration|plasma exposure]] during co-administration{{cite|doi=10.3389/fmolb.2026.1768402|anchor=515c056e}}{{cite|doi=10.1093/toxsci/kfaf118|anchor=b0aa6bb6}}. ===Neuroendocrine and immunological effects=== At a dose of 1.0 mg DMT/kg, ayahuasca produces moderate [[glossary:sympathomimetic|sympathomimetic effects]]: significant prolactin [[glossary:elevation]], cortisol elevation, and time-dependent lymphocyte [[glossary:modulation]] (CD4/CD3 decrease, NK cell increase — normalized within 24 hours){{cite|doi=10.1097/JCP.0b013e31823607f6|anchor=7868eafd}}. Diastolic [[glossary:blood-pressure]] increases approximately 9 mmHg at the 0.85 mg DMT/kg dose{{cite|pubmed=12660312|anchor=dd27b903}}. ===Open questions=== Three preparation-specific questions remain unresolved. First, the pharmacokinetic contribution of tetrahydroharmine's SERT inhibition relative to DMT's 5-HT₂A agonism has not been quantified in human studies. Second, no published human pharmacokinetic comparison exists between ''P. viridis'' and ''D. cabrerana'' as admixture substitutions — qualitative experiential differences reported in ethnographic accounts lack controlled verification. Third, the role of [[glossary:endogenous]] DMT production (detected in human brain tissue, consistent with INMT [[glossary:enzyme]] presence in the [[glossary:central-nervous-system|CNS]]) in modulating the exogenous ayahuasca response remains speculative.

[[substance:dmt]] is [[glossary:schedule-i]] under the 1971 United Nations [[glossary:convention-on-psychotropic-substances]]. However, the Convention applies to pure chemical substances — ''Banisteriopsis caapi'' and ''Psychotria viridis'' are [[glossary:unscheduled|not scheduled]] under the 1961, 1971, or 1988 UN [[glossary:drug-control|drug control conventions]]{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=bb02c28d}}. This treaty-level ambiguity has produced divergent national approaches: some jurisdictions criminalize ayahuasca brews as DMT preparations, while others exempt religious or traditional ceremonial use through specific legal carve-outs.

Jurisdiction	Classification	Key provisions
United States (federal)	Schedule I (Controlled Substances Act)	DMT is Schedule I; manufacturing, distributing, or possessing ayahuasca is a federal felony. Two religious organizations hold RFRA exemptions: União do Vegetal (UDV; upheld by Supreme Court 2006, ''Gonzales v. O Centro'') and Santo Daime.{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=d23e0843}}
United States (state — Colorado)	Decriminalized (Proposition 122, November 2022)	Natural psychedelics including ayahuasca decriminalized at state level. Several municipalities (Oakland CA, Santa Cruz CA, Denver CO) have adopted deprioritization resolutions.
Brazil	Legal for ceremonial use	CONAD regulations since 1987 authorize religious and ceremonial use; re-affirmed and expanded in 2010. Commercial non-ritualistic use and export prohibited.
Peru	Legal for traditional use	Traditional and ceremonial use legally recognized. National Institute of Culture declared ceremonial use a cultural heritage (2008). Plants not specifically criminalized.
Canada	Schedule III (Controlled Drugs and Substances Act)	DMT is Schedule III. Religious exemptions for UDV and Santo Daime reported.{{flag|citation-needed}}
United Kingdom	Class A (Misuse of Drugs Act 1971)	Prohibited due to DMT content. No religious exemption. Possession: up to 7 years imprisonment; supply: up to life imprisonment.
Netherlands	Prohibited (Opium Act)	Supreme Court 2019: ayahuasca prohibited due to DMT content; prior lower-court religious use exemptions reversed.
Germany	Illegal (BtMG)	DMT is controlled under the Narcotics Act (Betäubungsmittelgesetz). Preparation of ayahuasca is illegal; plants alone are not explicitly listed but preparation is prohibited.
Australia	Schedule 9 (Poisons Standard)	DMT is a prohibited substance. No religious exemptions known. No known prosecutions for personal ceremonial use reported.
Colombia	Traditional use protected	Indigenous ceremonial use is legally protected under constitutional indigenous rights. Commercial and tourist use occupies a legal grey area.{{flag|citation-needed}}

In jurisdictions where domestic law criminalizes DMT without explicit plant exemptions (United Kingdom, Netherlands, Germany), [[glossary:possession]] of ayahuasca brews is treated as possession of a controlled substance. Where religious or cultural exemptions exist (Brazil, Peru, United States for RFRA holders), the preparation occupies a legally defined carve-out from general [[glossary:prohibition]]. ===Detection=== Standard 5-panel and 10-panel urine immunoassay drug screens do not test for DMT or beta-carboline alkaloids. [[glossary:detection]] requires specialized [[glossary:analytical-method|analytical methods]] — GC-MS or LC-MS/MS. In a study of 14 religious users, DMT and beta-carbolines were detectable in saliva and serum for approximately 24 hours post-[[glossary:ingestion]]{{cite|doi=10.1002/dta.2955|anchor=acbc1580}}.

Ayahuasca produces a deeply introspective serotonergic [[substance_class:psychoactive/psychedelic]] state in which prominent somatic engagement — [[effect:nausea]], purging, and visceral body sensations — is as central to the experience as visual or cognitive alterations. [[glossary:set-and-setting]] exert unusually strong [[glossary:modulation]] on experiential character, and brew-to-brew composition variability introduces a further axis of unpredictability: two servings from the same ceremony may deliver substantially different alkaloid loads to any given individual. The experiential profile overlaps most closely with high-dose psilocybin — comparable duration (4–8 hours versus 4–6 hours), similar visual complexity, and shared [[effect:ego-dissolution|ego-dissolution]] [[glossary:phenomenology]] — but with substantially greater gastrointestinal [[glossary:distress]] and a qualitatively distinct emotional-cathartic character that users and researchers consistently distinguish from the psilocybin experience.

===Toxicity=== A systematic thematic review of 78 articles concluded that ayahuasca is generally safe in healthy populations under controlled conditions, with serious adverse events rarely reported{{cite|doi=10.1177/10915818241230916|anchor=5134cd55}}. No published [[glossary:case-report|case reports]] of death attributable solely to traditional ayahuasca consumed without concurrent serotonergic drugs were identified in the peer-reviewed literature. Among the beta-carbolines, [[substance:harmaline]] showed the most preclinical [[glossary:toxicity]] concerns{{cite|doi=10.1177/10915818241230916|anchor=6c4752d2}}. No formal [[glossary:lethal-dose|LD50]] (mg/kg, acute, single dose) has been published for ayahuasca as a preparation. The approximate claim that the lethal dose is approximately 50 times a regular dose cannot be verified against a primary published source{{flag|safety-citation-needed}}. The closest available data come from a rat developmental toxicity study in which daily oral dosing at 4× and 8× human equivalent doses over gestation days 6–20 produced mortality rates of 44% and 52% respectively{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=2e7ee1e6}}{{flag|additional-citations-needed}} — consistent with a wide therapeutic ratio but derived from a subchronic, not acute, dosing protocol. Moderate [[glossary:sympathomimetic]] cardiovascular effects are documented: diastolic [[glossary:blood-pressure]] increase of approximately 9 mmHg at 0.85 mg [[substance:dmt]]/kg, [[glossary:tachycardia]], and significant prolactin and cortisol [[glossary:elevation]]{{cite|pubmed=12660312|anchor=34d92d1a}}{{cite|doi=10.1097/JCP.0b013e31823607f6|anchor=4e392f6a}}. These effects are not comparable in magnitude to sympathomimetic [[substance_class:psychoactive/stimulant|stimulants]]. ====Developmental toxicity==== Da Motta and colleagues (2018) administered ayahuasca orally to rats on gestation days 6–20 at 1×, 2×, 4×, and 8× human equivalent doses. At 4× and 8× doses, maternal mortality reached 44–52% with kidney injury. The 2× dose produced neuronal loss in hippocampal CA1 region. The 8× dose produced neuronal loss in hippocampus and raphe nuclei, delayed intrauterine growth, fetal soft-tissue anomalies, and embryo deaths{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=793e1e89}}{{flag|additional-citations-needed}}. These data establish a clear signal for developmental toxicity; formal [[glossary:inference|extrapolation]] to humans is limited but the finding constitutes a [[glossary:contraindication]] for use during pregnancy. ====Contaminant and adulterant risk==== Ayahuasca preparations sold in ceremonial or commercial contexts are subject to multiple contamination vectors: * '''Alkaloid variability:''' No standardized quality control exists for ceremonial preparations. Inter-batch DMT concentration varies from 0.05 to 14.2 mg/mL{{cite|pubmed=16149328|anchor=ffeb114f}}, making dose estimation unreliable without analytical verification. * '''Undisclosed admixture plants:''' Ceremonial preparations may include additional botanicals — notably tobacco (''Nicotiana''), ''Brugmansia'', or ''Datura'' species containing [[substance_class:chemical/tropane]] alkaloids ([[substance:scopolamine]], atropine) — without disclosure. Addition of ''Brugmansia'' or ''Datura'' creates anticholinergic toxidrome risk ([[effect:delirium]], [[glossary:hyperthermia]], tachycardia) mechanistically distinct from and additive to ayahuasca's serotonergic effects. * '''Microbial contamination:''' Aqueous decoctions stored improperly can support microbial growth. While alkaloid content remains stable at room temperature for approximately 80 days{{cite|pubmed=16149328|anchor=9c4097d4}}, microbiological stability data have not been published. * '''Commercial preparations:''' Brews sold through retreat operations or online sources may contain non-botanical adulterants or misrepresented [[glossary:potency]]. No ISO/IEC-accredited testing framework or Certificate of Analysis standard exists for ayahuasca preparations. Standard Ehrlich reagent reacts with [[substance_class:chemical/indole-alkaloid|indole alkaloids]] including DMT (purple color) and beta-carbolines, confirming the presence of [[substance_class:chemical/tryptamine]] alkaloids but not quantifying concentration or detecting non-[[substance_class:chemical/indole]] adulterants. ===Psychological risks=== Acute psychological [[glossary:adverse-effects]] include [[effect:anxiety]], fear, [[effect:paranoia]], [[effect:confusion]], perceptual overwhelm, and transient psychotic-like symptoms. These are dose-dependent — the intensity of [[effect:ego-dissolution]] and visionary content correlates positively with peak DMT serum concentration{{cite|doi=10.1162/jocn_a_02003|anchor=25a4083c}}{{flag|additional-citations-needed}}. A systematic review of 18 prospective studies documented that a subset of naturalistic users from retreat settings experienced persistent psychiatric complications including anxiety, depressive episodes, and [[effect:thought-disorganization]]{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=7c4c39a6}}{{flag|additional-citations-needed}}. [[glossary:psychosis]] precipitation is a risk in individuals with personal or family history of psychotic [[glossary:disorder|disorders]]; no published prevalence estimate specific to ayahuasca-induced psychosis was identified. Challenging psychological experiences are common at higher doses and in uncontrolled settings. Ceremonial contexts with experienced facilitators are associated with lower acute adverse event rates in observational data{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=c09ad83a}}. Post-session psychotherapeutic integration is supported by observational evidence for reducing adverse psychological sequelae and optimizing long-term outcomes{{cite|doi=10.1016/j.pnpbp.2026.111634|anchor=f0688034}}. ===Tolerance and dependence=== No behavioral [[glossary:tolerance]] development across sessions has been documented in regular ritual users in published observational data{{cite|doi=10.1017/S109285292400213X|anchor=309b8296}}{{cite|doi=10.3390/ph13110334|anchor=9e1b8a17}}. Acute within-session psychological tolerance to DMT has been observed during extended intravenous DMT administration{{cite|doi=10.1007/s00018-024-05353-6|anchor=8167acbc}}. In naturalistic Santo Daime settings, long-term users may show partial mitigation of mental imagery effects, suggesting possible neuroadaptive compensation{{cite|doi=10.1162/jocn_a_02003|anchor=67fa6e3e}}. No physical dependence or characteristic [[glossary:withdrawal]] has been documented{{cite|doi=10.1080/02791072.2016.1188225|anchor=d06f3f2a}}{{cite|doi=10.3390/ph13110334|anchor=19427c4a}}. Anti-addictive properties are suggested by the published evidence: a systematic review found that 4 of 5 human observational studies showed reductions in substance [[glossary:dependence]] symptoms among ayahuasca users{{cite|doi=10.1080/02791072.2016.1188225|anchor=66685b9c}}. Long-term cognitive safety has been assessed in a cross-sectional study (n=48) of religious users with over 20 years of regular ayahuasca use: no cognitive decline was detected, and experienced users showed higher working memory scores compared to beginners{{cite|doi=10.1007/s00406-024-01817-9|anchor=897d53a7}}{{flag|additional-citations-needed}}. ===Drug interactions=== The reversible MAO-A [[glossary:inhibition]] produced by beta-carboline alkaloids creates the primary interaction hazard. Unlike irreversible MAOIs (phenelzine, tranylcypromine), the duration of MAO-A inhibition from [[substance:harmine]] and harmaline is limited to the session window — but co-administration with serotonergic drugs within that window carries risk of '''serotonin syndrome''', a potentially fatal condition characterized by hyperthermia, neuromuscular rigidity, autonomic instability, and altered mental status. '''Serotonergic drugs (SSRIs, SNRIs):''' Fluoxetine and paroxetine are strong [[glossary:cyp2d6]] [[glossary:inhibitor|inhibitors]]; PBPK modeling predicts they significantly increase both DMT and harmine [[glossary:plasma-concentration|plasma exposure]] when co-administered{{cite|doi=10.3389/fmolb.2026.1768402|anchor=b46e29dc}}{{flag|additional-citations-needed}}. The pharmacodynamic risk ([[glossary:serotonin]] [[glossary:accumulation]] from SSRI + MAO-A inhibition) compounds the pharmacokinetic risk (elevated DMT and harmine from CYP2D6 inhibition). Minimum washout of 2 weeks from most SSRIs and SNRIs is recommended before ayahuasca use; fluoxetine requires 5 weeks due to the long [[glossary:half-life]] of its active metabolite norfluoxetine. '''Irreversible MAOIs (phenelzine, tranylcypromine, moclobemide):''' Additive MAO-A inhibition producing prolonged and intensified effects with high [[glossary:serotonin-syndrome]] risk. '''Tramadol:''' Combined serotonergic [[glossary:potentiation]] and CYP2D6 interaction; [[effect:seizure-threshold-reduction]]. '''Lithium:''' [[glossary:seizure]] risk has been noted in [[index:harm-reduction|harm reduction]] literature and clinical practice guidelines, with mechanistic plausibility, but specific peer-reviewed case reports were not identified in this review{{flag|safety-citation-needed}}. '''Stimulants (amphetamines, cocaine):''' Additive sympathomimetic and serotonergic effects; cardiovascular risk compounded. '''Antipsychotics:''' Pharmacodynamic antagonism at [[glossary:5-ht2a]] may blunt ayahuasca effects; QTc prolongation risk with concurrent use. ===Contraindications=== '''Absolute contraindications:''' * '''Concurrent serotonergic medication''' (SSRIs, SNRIs, MAOIs, [[substance:tramadol]]): serotonin syndrome risk via pharmacokinetic (CYP2D6 inhibition) and pharmacodynamic (serotonin accumulation) mechanisms{{cite|doi=10.3389/fmolb.2026.1768402|anchor=3ff8447b}}. * '''Pregnancy:''' Developmental toxicity demonstrated in rats — neuronal loss in hippocampal CA1 region at 2× human equivalent dose; embryolethality and fetal anomalies at 8× dose{{cite|doi=10.1016/j.reprotox.2018.03.002|anchor=cfd3d6d8}}. * '''Active psychotic disorders''' or personal/family history of schizophrenia or schizotypal personality disorder: psychosis precipitation risk with serotonergic psychedelics. '''Relative contraindications:''' * '''Severe cardiovascular disease''' ([[glossary:hypertension|uncontrolled hypertension]], [[glossary:arrhythmia]], recent cardiac events): sympathomimetic effects include tachycardia and diastolic blood pressure elevation of approximately 9 mmHg at 0.85 mg DMT/kg{{cite|pubmed=12660312|anchor=820af24f}}{{flag|additional-citations-needed}}. * '''Acute bipolar disorder:''' [[effect:mania]] risk not fully characterized but mechanistically plausible given serotonergic [[glossary:activation]]. * '''Severe hepatic impairment:''' Harmine [[glossary:metabolism]] is hepatically dependent (CYP2D6 and CYP1A2 [[glossary:substrate|substrates]]); impaired [[glossary:clearance]] may prolong MAO-A inhibition and elevate DMT exposure. No clinical case reports of hepatotoxicity were identified{{flag|safety-citation-needed}}. * '''Lithium therapy:''' Seizure risk noted in harm reduction literature{{flag|safety-citation-needed}}.

[[substance:dmt]] is [[glossary:schedule-i]] under the 1971 United Nations [[glossary:convention-on-psychotropic-substances]]. However, the Convention applies to pure chemical substances, not to plants containing them — ''Banisteriopsis caapi'' and ''Psychotria viridis'' are [[glossary:unscheduled|not scheduled]] under the 1961, 1971, or 1988 UN [[glossary:drug-control|drug control conventions]]{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=570fcabf}}. This treaty-level ambiguity has been exploited by religious organizations and remains unresolved in multiple national jurisdictions.

Jurisdiction	Classification	Key provisions
United States (federal)	Schedule I (Controlled Substances Act)	DMT is Schedule I; manufacturing, distributing, or possessing ayahuasca is a federal felony. Two religious organizations hold RFRA exemptions: União do Vegetal (UDV; upheld by Supreme Court 2006, ''Gonzales v. O Centro'') and Santo Daime.{{cite|url=https://en.wikipedia.org/wiki/Legal_status_of_ayahuasca_by_country|anchor=10a1f881}}
United States (state — Colorado)	Decriminalized (Proposition 122, November 2022)	Natural psychedelics including ayahuasca decriminalized at state level. Several municipalities (Oakland CA, Santa Cruz CA, Denver CO) have adopted deprioritization resolutions.
Brazil	Legal for ceremonial use	CONAD regulations since 1987 authorize religious and ceremonial use; re-affirmed and expanded in 2010. Commercial non-ritualistic use and export prohibited.
Peru	Legal for traditional use	Traditional and ceremonial use legally recognized. National Institute of Culture declared ceremonial use a cultural heritage (2008). Plants not specifically criminalized.
Canada	Schedule III (Controlled Drugs and Substances Act)	DMT is Schedule III. Religious exemptions for UDV and Santo Daime reported.{{flag|citation-needed}}
United Kingdom	Class A (Misuse of Drugs Act 1971)	Prohibited due to DMT content. No religious exemption. Possession: up to 7 years imprisonment; supply: up to life imprisonment.
Netherlands	Prohibited (Opium Act)	Supreme Court 2019: ayahuasca prohibited due to DMT content; prior lower-court religious use exemptions reversed.
Germany	Illegal (BtMG)	DMT is controlled under the Narcotics Act (Betäubungsmittelgesetz). Preparation of ayahuasca is illegal; plants alone are not explicitly listed but preparation is prohibited.
Australia	Schedule 9 (Poisons Standard)	DMT is a prohibited substance. No religious exemptions known. No known prosecutions for personal ceremonial use reported.
Colombia	Traditional use protected	Indigenous ceremonial use is legally protected under constitutional indigenous rights. Commercial and tourist use occupies a legal grey area.{{flag|citation-needed}}

The treaty-level distinction between scheduled alkaloids and unscheduled [[glossary:plant-material|plant materials]] remains the central legal tension. In jurisdictions where domestic law criminalizes DMT without explicit plant exemptions (United Kingdom, Netherlands, Germany), [[glossary:possession]] of ayahuasca brews is treated as possession of a controlled substance. In jurisdictions with explicit religious or cultural exemptions (Brazil, Peru, United States for RFRA holders), the preparation occupies a legally defined carve-out from general [[glossary:prohibition]]. ===Detection=== Standard 5-panel and 10-panel urine immunoassay drug screens do not test for DMT or beta-carboline alkaloids. [[glossary:detection]] requires specialized [[glossary:analytical-method|analytical methods]] — GC-MS or LC-MS/MS. In a study of 14 religious users, DMT and beta-carbolines were detectable in saliva and serum for approximately 24 hours post-[[glossary:ingestion]], with cmax and AUC values higher in saliva than serum{{cite|doi=10.1002/dta.2955|anchor=333a1451}}.